Cancer Clinical Trials - Join clinical trials for Cancer in Canada

All Categories Medical Conditions » Cancers » Canada

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Conditions: HER2 + Breast Cancer; HER2 + Gastric Cancer; Squamous Cell Carcinoma of Head and Neck
Intervention: Drug: LJM716
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer

Condition: Metastatic Pancreas Cancer
Interventions: Drug: 5FU, leucovorin, oxaliplatin; Drug: Gemcitabine
Sponsors: Alberta Health Services; Alberta Health Services
Not yet recruiting - verified April 2012
Self-Management Intervention for Breathlessness in Lung Cancer

Conditions: Lung Cancer; Breathlessness
Intervention: Behavioral: Self-management Intervention
Sponsors: University Health Network, Toronto; University Health Network, Toronto; National Lung Cancer Partnership; Oncology Nursing Society Foundation; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified April 2012
Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: focal salvage HDR prostate brachytherapy
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Association of Radiation Oncology
Not yet recruiting - verified April 2012
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
Sentinel Node Biopsy in Endometrial Cancer

Conditions: Uterine Neoplasms; Sentinel Lymph Node Biopsy
Intervention: Procedure: Sentinel Lymph Node Biopsy
Sponsors: Hamilton Health Sciences Corporation; Hamilton Health Sciences Corporation; Juravinski Cancer Centre Foundation
Not yet recruiting - verified March 2012
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Condition: Non Small Cell Lung Cancer
Intervention: Drug: Ganetespib
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified May 2012
Night-time Compression Systems for Breast Cancer Related Lymphedema

Conditions: Breast Neoplasms; Lymphedema
Interventions: Behavioral: Night-time compression system garment; Behavioral: Day-time compression sleeve
Sponsors: University of Alberta; University of Alberta; Alberta Health Services; Canadian Breast Cancer Foundation
Recruiting - verified April 2012
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer

Condition: Prostatic Neoplasms
Intervention: Drug: Degarelix (Firmagon)
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Active, not recruiting - verified March 2012
The Effect of a Virtual Navigator on Colorectal Cancer Patient Empowerment

Condition: Colorectal Cancer
Interventions: Other: Oncology Interactive Navigator; Other: Routine Care
Sponsors: McGill University; McGill University
Recruiting - verified May 2012
A Phase II Multi-institutional Study Assessing Simultaneous In-field Boost Helical Tomotherapy for 1-3 Brain Metastases

Condition: Metastasis to Brain of Primary Cancer
Intervention: Radiation: Whole brain external beam radiation with simultaneous in-field boost
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; Ontario Institute for Cancer Research
Recruiting - verified February 2012
Dynamic Contrast Enhanced Computed Tomography (CT) for Head and Neck Cancer

Condition: Head and Neck Cancer
Intervention: Radiation: Dynamic Contrast Enhanced CT scan
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; London Regional Cancer Program, Canada
Not yet recruiting - verified March 2012
Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel

Condition: Breast Cancer
Intervention: Procedure: Fine needle aspiration assessing tumour TNFa levels
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Not yet recruiting - verified February 2012
Metabolic Effects of Treatment in Intermediate and High-Risk Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: University of Waterloo; University of Waterloo; Grand River Regional Cancer Centre
Recruiting - verified May 2012
Evaluation of Nutrition and Metabolism in Breast Cancer Patients

Condition: Breast Cancer
Interventions: Behavioral: Nutrition and Exercise Group; Behavioral: Yoga and Stretching Group
Sponsors: University of Waterloo; University of Waterloo; Grand River Regional Cancer Centre
Recruiting - verified February 2012
Long Term Outcomes of Breast Intensity-Modulated Radiation Therapy

Condition: Breast Cancer
Intervention: Radiation: BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; Canadian Institutes of Health Research (CIHR)
Enrolling by invitation - verified March 2012
Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer

Conditions: Colorectal Neoplasm; Biliary Tract Neoplasm; Liver Neoplasm
Interventions: Dietary Supplement: Whey protein and dietary supplements; Other: prehab exercise
Sponsors: McGill University Health Center; McGill University Health Center
Recruiting - verified February 2012
Renal Hypothermia During Partial Nephrectomy

Conditions: Renal Impairment; Kidney Diseases; Urologic Diseases; Cancer; Hypothermia; Kidney Cancer
Intervention: Procedure: Renal hypothermia
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified March 2012
Continuation Study of the Oral AKT Inhibitor GSK2110183

Condition: Cancer
Intervention: Drug: GSK2110183
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm

Conditions: Mucinous Cystic Tumor With Moderate Dysplasia; Mucinous Cystadenoma of Pancreas; Mucinous Cystadenocarcinoma of Pancreas; Benign Neoplasm of Pancreas
Intervention: Drug: Ethanol and Paclitaxel Injection
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; University of Western Ontario, Canada
Not yet recruiting - verified February 2012
Rectal Cancer: Local Staging, Re-staging and Assessment of Lymph Nodes Using Pet-Ct, CT-Perfusion and 3T MRI

Condition: Rectal Cancer
Intervention: Device: MRI,PET-CT and CT-Perfusion studies
Sponsors: London Health Sciences Centre; London Health Sciences Centre
Not yet recruiting - verified January 2012
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Condition: Breast Cancer
Intervention: Drug: trastuzumab emtansine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction

Condition: Malignant Tumor of Extrahepatic Bile Duct
Interventions: Device: WInged perimeter biliary stent insertion (Viaduct); Device: traditional polyethylene stent insertion (Cotton Huibregtse)
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified January 2012
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Condition: Melanoma
Interventions: Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: LY2495655; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Suspended - verified May 2012
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Conditions: Colon Cancer; Rectal Cancer
Intervention:
Sponsors: University of Michigan; University of Michigan; Early Detection Research Network
Recruiting - verified January 2012
A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer

Conditions: Pancreatic Cancer; Hypoxia
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Canadian Cancer Society
Recruiting - verified March 2012
Integrated Molecular Profiling in Advanced Cancers Trial

Conditions: Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Ovarian Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting - verified March 2012
Everolimus Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (Gastro Intestinal or Lung Origin)

Conditions: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
Interventions: Drug: Everolimus; Drug: Everolimus Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Interventions: Drug: Cabazitaxel XRP6258; Drug: Topotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

Condition: Clear Cell, Metastatic Renal Cell Carcinoma
Intervention: Drug: Sunitinib
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Pfizer
Not yet recruiting - verified December 2011
Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer

Condition: Lung Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified December 2011
Urine Metabolomics and Colorectal Cancer Screening

Conditions: Colorectal Cancer; Colorectal Polyps
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified December 2011
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Condition: Colorectal Cancer
Interventions: Drug: Tivozanib; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): Pilot Study

Conditions: Infection; Bone Neoplasms
Intervention: Procedure: Prophylactic Cefazolin Antibiotic Regimen
Sponsors: McMaster University; Michelle Ghert
Not yet recruiting - verified April 2012
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Conditions: Breast Cancer; Brain Metastases
Interventions: Drug: GRN1005; Drug: Trastuzumab
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified May 2012
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors

Conditions: Glioma; Metastatic Brain Cancer
Intervention: Device: ExAblate Transcranial System
Sponsors: InSightec; InSightec
Recruiting - verified March 2012
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Condition: Lung Neoplasms
Interventions: Drug: Afatinib; Drug: gefitinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer

Condition: Esophageal Cancer
Intervention:
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM)
Recruiting - verified November 2011
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
The Young Women's Breast Cancer Study

Condition: Breast Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified November 2011
A First-In-Human Study of RO5503781 in Patients With Advanced Malignancies, Except Leukemia

Condition: Neoplasms
Interventions: Drug: RO5503781; Drug: RO5503781
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Hypofractionated radiotherapy
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Association of Radiation Oncology
Active, not recruiting - verified April 2012
Comparing Robotics and Laparoscopy With Laparotomy/Open Surgery for Endometrial Cancer

Condition: Cancer of the Endometrium
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified November 2011
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012
BMS-936558 (MDX-1106) In Combination With Sunitinib or Pazopanib in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Sunitinib; Drug: Pazopanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012
Pilot Study Using a PET Gamma Probe to Evaluate Lymph Nodes in Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Procedure: lymphadenectomy; Procedure: therapeutic conventional therapy; Procedure: Positron Emission Tomography/ Computed Tomography; Radiation: fludeoxyglucose F 18
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified May 2012
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Conditions: Urologic Neoplasms; Metastatic Bladder Cancer; Urinary Tract Neoplasms
Interventions: Drug: OGX-427 600 mg; Drug: OGX-427 1000 mg; Drug: Placebo
Sponsors: OncoGenex Technologies; OncoGenex Technologies; OncoGenex Pharmaceuticals; PRA International
Recruiting - verified May 2012
Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Degarelix
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Not yet recruiting - verified November 2011
Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

Condition: Prostate Cancer
Interventions: Radiation: hypofractionation; Radiation: conventional
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Sir Mortimer B. Davis - Jewish General Hospital
Not yet recruiting - verified September 2011
Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Hypofractionated radiation
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified January 2012
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus

Conditions: Esophageal Cancer; Precancerous Condition
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2012
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Conditions: Breast Neoplasms; Neoplasm Metastasis
Interventions: Drug: afatinib; Drug: afatinib; Drug: Vinorelbine; Drug: Investigator's choice of treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Neoviderm in the Prevention of Radiation Dermatitis

Conditions: Breast Cancer; Head and Neck Cancer
Interventions: Other: Aveeno cream and Flamazine cream; Other: Neoviderm cream; Other: Aveeno cream and Flamazine cream; Other: Neoviderm cream
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Sir Mortimer B. Davis - Jewish General Hospital; Avario Healthcare Inc.
Recruiting - verified April 2012
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)

Condition: Oligometastatic Tumors
Interventions: Radiation: Stereotactic ablative radiotherapy; Radiation: palliative radiotherapy
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; London Regional Cancer Program, Canada; VU University of Amsterdam
Recruiting - verified December 2011
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Response of Patients on Surveillance for Prostate Cancer to Dutasteride

Condition: Prostate Cancer
Intervention: Drug: Dutasteride
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Odette Cancer Centre Genito-Urinary Disease Site Group
Completed - verified February 2012
FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: Stereotactic Body Radiation; Drug: Luteinizing Hormone Releasing Hormone (LHRH) Agonist
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Recruiting - verified September 2011
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
A Prospective Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer

Condition: Thyroid Neoplasms
Interventions: Drug: CPERT; Drug: GPERT
Sponsors: Alberta Health Services; Alberta Health Services; Natural Resources, Canada; Edmonton PET Centre
Recruiting - verified April 2012
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Condition: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: Drug: MEDI-573; Drug: Aromatase Inhibitor
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Breast Cancer and Exercise Trial in Alberta

Condition: Breast Neoplasms
Interventions: Other: Volume of Exercise; Moderate or High Volume; Other: Aerobic Exercise; Other: Aerobic Exercise
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified September 2011
A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer

Condition: Breast Cancer
Intervention: Genetic: ONCOTYPEDX Test
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Recruiting - verified May 2012
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Conditions: Prostate Neoplasms; Prostate Cancer
Interventions: Drug: Abiraterone acetate and prednisone; low-fat diet; Drug: Abiraterone acetate and prednisone; high-fat diet
Sponsors: Janssen-Ortho Inc., Canada; Janssen-Ortho Inc., Canada
Recruiting - verified April 2012
Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time

Condition: Prostatic Neoplasms
Interventions: Radiation: Image-guided radiotherapy; Radiation: Image-guided radiotherapy
Sponsors: CancerCare Manitoba; CancerCare Manitoba; Sunnybrook Health Sciences Centre
Recruiting - verified February 2012
Combination Statin, Acetylsalicylic Acid and Dutasteride Use in Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Completed - verified September 2011
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Condition: Endometrial Neoplasms
Interventions: Drug: PF-04691502; Drug: PF-05212384; Drug: PF-04691502; Drug: PF-05212384
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Acupuncture for the Immune System in Radiation Cancer Patients

Conditions: Gastrointestinal Neoplasms; Urogenital Neoplasms
Intervention: Procedure: Medical Acupuncture
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; BC Cancer Foundation
Active, not recruiting - verified August 2011
The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction

Conditions: Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases
Interventions: Drug: Botulinum Toxin Type A; Drug: 0.9% Sodium Chloride
Sponsors: University of British Columbia; University of British Columbia; Vancouver Coastal Health; Providence Health & Services
Recruiting - verified January 2012
Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Intervention: Radiation: Stereotactic Body Radiation Therapy
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified November 2011
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer

Condition: Pancreas Cancer
Interventions: Drug: gemcitabine; Drug: 5-fluorouracil
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Alkagin Paste in the Prevention of Radiation Dermatitis

Conditions: Anus Neoplasms; Rectal Neoplasms; Urogenital Neoplasms
Interventions: Other: Aveeno cream; Other: Alkagin paste
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Dr. Te Vuong; Avario Healthcare
Recruiting - verified May 2012
A Study on Patients' Preference of Herceptin (Trastuzumab) Subcutaneous Versus Intravenous Administration in Patients With HER2-Positive Early Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Neoadjuvant Chemotherapy vs. Chemoradiation for Resectable Esophageal Cancer

Conditions: Esophageal Cancer; Adenocarcinoma, Esophageal; Squamous Cell Carcinoma, Esophageal; Carcinoma, Gastroesophageal Junction
Interventions: Drug: carboplatin and paclitaxel; Other: Carboplatin paclitaxel plus concurrent radiotherapy
Sponsors: Capital District Health Authority, Canada; Gordon Buduhan; Capital Health, Canada
Recruiting - verified January 2012
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Condition: Advanced Rare Tumours
Interventions: Drug: Sunitinib; Drug: Temsirolimus
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012
Prostate Cancer Survivors Moving Toward Exercise (PROMOTE) Trial

Condition: Prostate Cancer
Interventions: Behavioral: Telephone Implementation Intention; Behavioral: Self-completed implementation intention
Sponsors: University of Alberta; University of Alberta
Active, not recruiting - verified August 2011
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: dasatinib
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012
Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer

Conditions: Bladder Cancer; Transitional Cell Carcinoma
Intervention:
Sponsors: University of British Columbia; University of British Columbia; Canadian Urologic Oncology Group
Not yet recruiting - verified July 2011
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Condition: Prostate Cancer
Intervention:
Sponsors: Abbott; Abbott; JSS Medical Research Inc.; CMX Research; CMX Research Inc
Recruiting - verified March 2012
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012
A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Conditions: Hepatocellular Carinoma; Liver Cancer; HCC
Interventions: Biological: JX-594 recombinant vaccina GM-CSF; Other: Best Supportive Care
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics
Recruiting - verified November 2011
Subcutaneous Lidocaine For Cancer-Related Pain

Condition: Cancer-related Pain
Interventions: Drug: Lidocaine; Drug: Placebo (normal saline)
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; BC Cancer Foundation
Recruiting - verified March 2012
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012
A Study of RO5458640 in Patients With Advanced Solid Tumors

Condition: Neoplasms
Intervention: Drug: RO5458640
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Increasing Colorectal Cancer Screening Uptake With a Patient Navigator

Condition: Colorectal Cancer
Interventions: Behavioral: Health counselling by nurse navigator; Behavioral: Usual primary care counselling
Sponsors: Cancer Care Ontario; Cancer Care Ontario; Canadian Institutes of Health Research (CIHR)
Recruiting - verified January 2012
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Conditions: Cervical Cancer; HPV Type 16/18 Infections
Intervention: Biological: GSK Biologicals' HPV vaccine 580299
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified March 2012
Using Pentamidine (OCZ103-OS) in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

Condition: Colorectal Cancer
Intervention: Drug: Pentamidine (OCZ103-OS), mFOLFOX6 or FOLFIRI
Sponsors: Oncozyme Pharma Inc.; Oncozyme Pharma Inc.
Recruiting - verified October 2011
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Conditions: Neoplasms; Neoplasm Metastasis; Pancreatic Cancer
Interventions: Drug: LY2157299; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Condition: Prostate Cancer
Intervention:
Sponsors: CMX Research; CMX Research; Ferring Pharmaceuticals
Recruiting - verified February 2012
Optimal Management of Malignant Dysphagia

Conditions: Malignant Dysphagia; Esophageal Cancer
Interventions: Radiation: Brachytherapy; Procedure: Stent insertion
Sponsors: McGill University Health Center; McGill University Health Center
Not yet recruiting - verified June 2011
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012
Femoral Bone Metastases

Conditions: Cancer; Metastatic Malignant Neoplasm to Femur; Risk of Fracture
Interventions: Procedure: Surgery Alone; Other: Combined Surgery and Radiation therapy
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified May 2012
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004 AM1)

Condition: Ovarian Cancer
Interventions: Drug: MK-1775; Drug: Placebo; Drug: paclitaxel; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012
Active Surveillance Magnetic Resonance Imaging Study

Condition: Prostate Cancer
Intervention: Device: MRI assisted TRUS guided biopsy
Sponsors: Canadian Urology Research Consortium; Canadian Urology Research Consortium; OICR; Eigen
Recruiting - verified March 2012
Multimodal Prehabilitation for Colorectal Surgery

Conditions: Colorectal Cancer; Colorectal Cancer Stage III
Interventions: Behavioral: multimodal prehabilitation; Behavioral: multimodal prehabilitation
Sponsors: McGill University Health Center; McGill University Health Center; Society of American Gastrointestinal and Endoscopic Surgeons
Recruiting - verified April 2012
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Biological: BMS-936558; Biological: BMS-936558
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Docetaxel; Drug: Combination of ganetespib and docetaxel
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified November 2011
A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy

Condition: Non-small Cell Lung Cancer
Interventions: Radiation: EBR plus HDRIB; Radiation: EBR
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Canadian Cancer Society
Recruiting - verified March 2012
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Condition: Head and Neck Neoplasms
Interventions: Drug: Placebo; Drug: Afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

Condition: Advanced Solid Tumors
Intervention: Drug: MEK162 + RAF265
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Condition: Advanced Cancer
Interventions: Drug: PF-04691502; Drug: PD-0325901; Drug: PF-04691502; Drug: irinotecan; Drug: PF-05212384; Drug: irinotecan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Acupressure in Controlling Nausea in Young Patients With Central Nervous System or Solid Tumors Receiving Cisplatin-Containing Chemotherapy

Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: iodine I 125; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Intervention: Radiation: Adaptive Radiation
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: PX-866
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Oncothyreon Canada Inc.
Recruiting - verified March 2012
Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer Undergoing Chemotherapy

Conditions: Carcinoma, Non-Small-Cell Lung; Cancer of the Gastrointestinal Tract
Interventions: Behavioral: Standard Exercise; Behavioral: Qigong Exercise
Sponsors: McGill University; McGill University; Jewish General Hospital
Active, not recruiting - verified February 2011
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Other: Best Supportive Care; Drug: Panitumumab
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: MLN9708 plus Melphalan and Prednisone; Drug: MLN9708 plus Melphalan and Prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Computer-Generated Quality of Life Assessment Program for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)

Condition: Non Small Cell Lung Cancer
Interventions: Procedure: Physician Receives QoL results; Procedure: Physician Does not receive the results
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Mount Sinai Hospital, Canada
Completed - verified December 2011
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Solid Tumor
Intervention: Drug: BEZ235 + MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: pomalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Study to Compare Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: pomalidomide; Drug: dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS I

Condition: Lung Cancer
Intervention:
Sponsors: Allegro Diagnostics, Corp.; Allegro Diagnostics, Corp.; Beth Israel Deaconess Medical Center; Columbia University; Vanderbilt University; University of British Columbia; University of Pennsylvania; New York University; Temple University; Indiana University; University of Alabama at Birmingham; University of Virginia; University of Missouri-Columbia; Louisiana State University Health Sciences Center in New Orleans; University of Dublin, Trinity College; Georgia Institute for Clinical Research, LLC
Active, not recruiting - verified May 2012
A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Breast Cancer Research Foundation
Recruiting - verified July 2011
Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Conditions: Locally Advanced or Metastatic Medullary Thyroid Cancer; Medullary Thyroid Cancer
Intervention: Behavioral: Patient outreach
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified November 2011
Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

Conditions: Pancreatic Cancer; Unresectable Pancreatic Cancer
Intervention: Radiation: stereotactic body radiotherapy
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified December 2011
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: VGX 3100; Biological: Placebo
Sponsors: Inovio Pharmaceuticals; Inovio Pharmaceuticals
Recruiting - verified May 2012
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel; Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
A Study of RO5185426 in Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer

Condition: Breast Cancer
Intervention: Other: DE-CEDM and CE-BMRI
Sponsors: GE Healthcare; GE Healthcare
Recruiting - verified January 2012
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Intervention: Drug: Tivozanib
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.
Recruiting - verified September 2011
Intervention to Improve Continuity of Care in Lung Cancer Patients

Condition: Lung Cancer
Intervention: Other: Multi-faceted intervention to improve continuity of care
Sponsors: Laval University; Laval University; Canadian Cancer Society
Recruiting - verified January 2012
A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012
Can Exercise Improve Cancer Associated Cognitive Dysfunction?

Condition: Breast Cancer
Intervention: Behavioral: Exercise
Sponsors: University of British Columbia; University of British Columbia; Canadian Breast Cancer Foundation
Recruiting - verified February 2012
BAY73-4506 Probe Substrate Study

Condition: Neoplasms
Interventions: Drug: Regorafenib (BAY73-4506) + warfarin + omeprazole + midazolam; Drug: Regorafenib (BAY73-4506) + rosiglitazone
Sponsors: Bayer; Bayer
Active, not recruiting - verified April 2012
BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Condition: Advanced Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2012
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer

Condition: Operable T2-3N+M0 Rectal Cancer (Stage III)
Interventions: Drug: FOLFOX; Radiation: high dose rate endorectal brachytherapy
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Sir Mortimer B. Davis - Jewish General Hospital; Sanofi-Aventis
Recruiting - verified January 2011
Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients

Condition: Metastatic Breast Cancer
Interventions: Biological: CP-675,206; Radiation: External local radiation therapy
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Terminated - verified March 2012
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: imetelstat sodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
RO4929097 in Treating Patients With Recurrent Invasive Gliomas

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Completed - verified February 2012
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: capecitabine; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified October 2011
Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST)

Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Regorafenib (BAY 73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Active, not recruiting - verified May 2012
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Conditions: Squamous Cell Carcinoma (SCC) of the Oral Cavity; Squamous Cell Carcinoma of the Soft Palate
Interventions: Biological: LI plus CIZ; Other: Standard of Care (SOC); Biological: LI + SOC
Sponsors: CEL-SCI Corporation; CEL-SCI Corporation; Teva Pharmaceutical Industries; Orient Europharma Co., Ltd.
Recruiting - verified January 2012
Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel

Condition: Prostate Cancer
Interventions: Drug: cediranib maleate; Drug: dasatinib
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Carboplatin/Paclitaxel/MEDI-575; Drug: Carboplatin/Paclitaxel; Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases

Conditions: Colorectal Cancer; Liver Metastases
Intervention: Drug: Panitumumab, Oxaliplatin, 5-FU
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified May 2012
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Condition: Prostate Cancer Metastatic
Intervention: Drug: CABAZITAXEL
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Condition: Locally Recurrent or Metastatic Breast Cancer
Interventions: Drug: Imetelstat sodium; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: Geron Corporation; Geron Corporation
Active, not recruiting - verified March 2012
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Condition: Glioblastoma
Intervention: Drug: PX-866
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Oncothyreon Inc.
Recruiting - verified December 2011
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Phase 1 and 2 Study of PX-866 and Cetuximab

Conditions: Incurable Metastatic Colorectal Carcinoma; Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab; Drug: Cetuximab; Drug: PX-866 and cetuximab; Drug: Cetuximab
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified April 2012
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

Conditions: Melanoma; Metastatic Melanoma to the Brain
Intervention: Drug: GSK2118436
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified November 2011
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

Condition: Endometrial Cancer
Intervention: Drug: BN83495
Sponsors: Ipsen; Ipsen
Terminated - verified July 2011
Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases

Condition: Bone Metastases
Interventions: Drug: Dexamethasone; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified March 2012
ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Condition: Non Squamous, Non-small-cell Lung Cancer
Interventions: Drug: Tivantinib (ARQ 197) plus erlotinib; Drug: ARQ 197 placebo plus erlotinib
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; Daiichi Sankyo Development Limited; ArQule
Active, not recruiting - verified May 2012
A Degarelix Trial in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Zoladex
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Terminated - verified May 2012
Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole

Condition: Pancreatic Cancer
Intervention: Drug: Pimonidazole hydrochloride
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified October 2011
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Condition: Melanoma
Interventions: Drug: GSK1120212; Drug: Chemotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: carboplatin; Drug: Paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)

Condition: Neoplasms Malignant
Interventions: Drug: dalotuzumab + MK-2206; Drug: dalotuzumab + MK-0752; Drug: Dalotuzumab + MK-8669 (ridaforolimus)
Sponsors: Merck; Merck
Recruiting - verified May 2012
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: wild-type reovirus; Drug: cyclophosphamide; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Suspended - verified May 2012
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012
Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy

Condition: Locally Advanced Breast Cancer (LABC)
Intervention: Procedure: FLT PET and BOLD MRI scan
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG)
Recruiting - verified March 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Study in Non-Small Cell Lung Cancer

Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Cixutumumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified April 2012
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: Dacarbazine (DTIC)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: cognitive assessment; Procedure: quality-of-life assessment; Radiation: intensity-modulated radiation therapy; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

Condition: Breast Cancer
Intervention: Device: MRS
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasibility Study

Condition: Localized Low-Risk Prostate Cancer
Intervention: Device: MRgFUS Treatment
Sponsors: InSightec; InSightec
Recruiting - verified February 2012
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Conditions: Non Small Cell Lung Cancer; NSCLC
Interventions: Drug: OSI-906; Drug: Erlotinib; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
Art Therapy Intervention for Breast Cancer Patients

Condition: Breast Cancer
Intervention: Other: art therapy
Sponsors: McGill University Health Center; McGill University Health Center; The Cedars Cancer Institute
Recruiting - verified August 2011
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Condition: Metastatic Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Available - verified April 2012
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cediranib maleate; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified October 2010
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Conditions: Bladder Neoplasm; Intravesical Drug Administration; Neoplasm Recurrence, Local; Transitional Cell, Carcinoma; Carcinoma in Situ; Mycobacterium
Intervention: Biological: EN3348
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified February 2012
A Study of Nilotinib in Growing Vestibular Schwannomas

Conditions: Volumetric Tumor Response and Lack of Tumor Progression; Quality of Life of Patients on Nilotinib Versus Not
Intervention: Drug: Nilotinib
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Novartis
Recruiting - verified June 2011
Pre-Operative Assessment of Chest Wall Invasion in Non-Small Cell Lung Cancer Using Pre-Operative, Surgeon Performed Ultrasound

Condition: Non Small Cell Lung Cancer
Intervention: Procedure: Transthoracic Ultrasound
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified November 2011
RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Conditions: Endometrial Cancer; Kidney Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: temsirolimus; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer

Condition: Cancer
Interventions: Drug: GSK1120212; Drug: Gemcitabine; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction

Condition: Breast Cancer
Interventions: Drug: Tamoxifen Citrate; Drug: Placebo
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); St. Jude Children's Research Hospital; University Health Network, Toronto; Emory University; University of Michigan
Recruiting - verified February 2012
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Custirsen Sodium, Docetaxel, Prednisone; Drug: Docetaxel, Prednisone
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; OncoGenex Technologies
Recruiting - verified May 2012
Conventional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients

Condition: Prostate Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Biological: GSK580299 (Cervarix™)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Conditions: Human Papillomavirus Infection; Cervical Neoplasia
Interventions: Procedure: Gynaecological follow-up; Biological: Cervarix™; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Condition: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions: Drug: OSI-906; Drug: erlotinib; Drug: placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified April 2012
A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia

Conditions: Leukemia; Solid Tumours
Intervention: Drug: SB939
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified April 2012
Computed Tomography (CT) Colonography Versus Optical Colonoscopy

Condition: Colonic Neoplasia
Intervention:
Sponsors: University of British Columbia; University of British Columbia; Canadian Society of Intestinal Research
Recruiting - verified April 2012
Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate

Condition: Prostate Cancer
Interventions: Radiation: Iodine 125 standard loose brachytherapy seeds; Radiation: AnchorSeed Iodine 125 brachytherapy prostate implant
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; BrachySciences
Active, not recruiting - verified June 2011
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Suspended - verified February 2012
A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified April 2012
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

Condition: Neoplasms
Interventions: Drug: BIBW 2992 low dose; Drug: BIBW 2992 medium dose; Drug: BIBW 2992 high dose; Drug: pemetrexed; Drug: pemetrexed; Drug: pemetrexed; Drug: pemetrexed; Drug: pemetrexed; Drug: pemetrexed; Drug: BIBW 2992 low dose 6 day; Drug: BIBW 2992 high dose 6 day; Drug: BIBW 2992 medium dose 6 day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence

Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Oncolytics Biotech; Oncolytics Biotech
Recruiting - verified March 2012
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011
Study Evaluating Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Metastatic Breast Cancer Patients

Conditions: Advanced Solid Tumours; Breast Cancer
Interventions: Drug: pantoprazole sodium for injection; Drug: doxorubicin hydrochloride injection
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting - verified March 2012
MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Condition: Her2 Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) and Exemestane; Drug: Placebo and Exemestane
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012
Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients

Conditions: Neoplasms, Colorectal; Colorectal Cancer; Colorectal Carcinoma
Intervention: Other: (supplement) Calcium and Magnesium
Sponsors: Alberta Health Services; Alberta Health Services
Not yet recruiting - verified April 2012
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Conditions: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine; Drug: Cytarabine; Drug: Methotrexate; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified November 2011
A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Condition: Melanoma
Interventions: Drug: rIL-21; Drug: Dacarbazine
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Conditions: Neoplasms; Breast Neoplasms; Breast Cancer
Interventions: Drug: AZD8931; Drug: anastrozole; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012
High Dose Vitamin D Study

Condition: Colorectal Cancer
Intervention: Drug: Vitamin D
Sponsors: University of British Columbia; University of British Columbia; Lotte and John Hecht Memorial Foundation
Recruiting - verified November 2011
Evaluation of the Use of Multimedia to Enhance Patient and Family Understanding

Condition: The Role of Multimedia on Retention and Comprehension of Key Concepts for Surgical Options in Newly Diagnosed Breast Cancer Patients.
Interventions: Other: This group of patients will be exposed to multimedia; Other: No Media
Sponsors: McGill University Health Center; McGill University Health Center
Enrolling by invitation - verified April 2012
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: AT9283
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012
Effects of Exemestane on Bone Strength

Conditions: Osteoporosis; Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Canadian Breast Cancer Research Alliance
Active, not recruiting - verified June 2010
Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Hypofractionated radiotherapy
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Association of Radiation Oncology
Active, not recruiting - verified September 2011
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Foretinib; Drug: Lapatinib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified April 2012
Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases

Conditions: Bone Metastases; Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; AstraZeneca
Active, not recruiting - verified January 2012
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Condition: Non-small Cell Lung Cancer
Interventions: Drug: imetelstat; Drug: Bevacizumab
Sponsors: Geron Corporation; Geron Corporation
Active, not recruiting - verified May 2012
Pleural Ultrasonography in Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: thoracic ultrasound; Procedure: pleural aspiration
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Fonds de la Recherche en Santé du Québec; Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Society of University Surgeons
Completed - verified June 2011
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer

Condition: Recurrent Breast Cancer
Intervention: Drug: Foretinib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Condition: Prostate Cancer
Intervention: Other: MRI examination
Sponsors: Radboud University; Radboud University; Siemens AG; Mount Vernon Hospital; Multi-Imagem and CDPI, Rio de Janeiro, Brasil; Norwegian University of Science and Technology; University of California, Los Angeles; University Hospital, Ghent; Johns Hopkins University; German Cancer Research Center; Medical University of Vienna; University Health Network, Toronto; University of Heidelberg
Recruiting - verified July 2011
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cediranib maleate; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified June 2011
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Condition: Venous Thromboembolism
Interventions: Drug: Warfarin; Drug: Innohep®
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified February 2012
A Feasibility Study to Compare the Benefits of Endoscopic Tumor Clip Placement and 3T-MRI Simulation for Accurate Target Volume Definition for Rectal Cancer Patients Undergoing Pre-operative Chemoradiation

Condition: Rectal Cancer
Intervention: Radiation: Radiation
Sponsors: Alberta Health Services; Alberta Health Services; IGAR Image guided adaptive radiotherapy
Recruiting - verified April 2012
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy

Condition: Non-small-cell Lung Cancer
Intervention: Drug: AUY922
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
OGX-427 in Castration Resistant Prostate Cancer Patients

Condition: Castration Resistant Prostate Cancer
Interventions: Drug: OGX-427 and Prednisone; Drug: Prednisone
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; OncoGenex Technologies, Inc.
Recruiting - verified December 2011
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Condition: Neoplasms Malignant
Intervention: Drug: Crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Dose Finding and Safety Study of Oral LDE225 in Children

Conditions: Medulloblastoma,; Rhabdomyosarcoma,; Neuroblastoma,; Hepatoblastoma,; High Grade Glioma,; Astrocytoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer

Condition: Pancreatic Neoplasms
Interventions: Drug: Leucovorin; Drug: OXALIPLATIN; Drug: Capecitabine; Drug: 5-Fluorouracil
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified February 2012
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

Conditions: Metastatic Breast Cancer; Trastuzumab; BKM120; HER2+
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

Condition: Oral Cavity Cancer
Intervention: Drug: PF-00299804/Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Pfizer
Recruiting - verified September 2011
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

Conditions: Lung Neoplasms; Carcinoma; Cancer of the Lung; Non-Small-Cell Lung Carcinoma
Interventions: Drug: Cetuximab; Drug: Cisplatin; Drug: Vinorelbine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Eli Lilly and Company
Active, not recruiting - verified April 2012
A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: IPI-926 plus gemcitabine; Drug: Placebo plus gemcitabine
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Active, not recruiting - verified November 2011
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

Condition: Breast Cancer
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Completed - verified November 2011
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Condition: Advanced Non-clear Cell Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: Sunitinib
Sponsors: Duke University; Duke University; Novartis; Pfizer
Recruiting - verified February 2012
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: IMC-1121B; Biological: IMC-18F1; Drug: mFOLFOX-6
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Active, not recruiting - verified April 2012
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Conditions: Ovarian Cancer; Fallopian Cancer; Peritoneal Cancer
Intervention: Drug: ENMD-2076
Sponsors: EntreMed; EntreMed
Active, not recruiting - verified August 2011
A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

Condition: Metastatic Sarcoma
Intervention: Drug: SB939
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified April 2012
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer

Condition: Kidney Cancer
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified September 2011
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection

Conditions: Cervical Cancer; Precancerous Condition
Intervention: Device: Multispectral Digital Colposcope (MDC)
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; National Cancer Institute (NCI)
Not yet recruiting - verified July 2011
Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity

Condition: Colorectal Neoplasms
Interventions: Drug: Glutamine; Drug: Calcium and Magnesium
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified April 2012
Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

Condition: Epithelial Ovarian Cancer
Intervention: Procedure: Seprafilm™
Sponsors: University of British Columbia; University of British Columbia; Genzyme
Recruiting - verified November 2011
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified March 2011
Reducing Pain and Disability After Breast Cancer Surgery

Conditions: Breast Cancer; Chronic Pain
Interventions: Procedure: Thoracic Paravertebral Block (TPVB); Procedure: Local Anesthetic
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Breast Cancer Foundation
Recruiting - verified July 2011
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus Iniparib
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified March 2012
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Conditions: Advanced Gastric Cancer; Gastro-esophageal Junction Cancer
Interventions: Drug: AUY922; Drug: Docetaxel or Irinotecan
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012
A Study in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: BMS-908662; Drug: BMS-908662; Drug: Cetuximab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified March 2011
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: olaparib; Drug: paclitaxel; Drug: carboplatin; Drug: paclitaxel; Drug: Drug: carboplatin
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012
Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Condition: Relapsed Multiple Myeloma
Interventions: Drug: Dexamethasone; Drug: Lenalidomide; Drug: Carfilzomib
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Active, not recruiting - verified May 2012
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: HDAC inhibitor SB939
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified March 2012
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: ABT-888; Drug: pegylated liposomal doxorubicin; Drug: temozolomide
Sponsors: Abbott; Abbott
Active, not recruiting - verified May 2012
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Conditions: Castrate-Resistant Prostate Cancer; Hormone Refractory Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: Isotonic, 0.9% sodium chloride
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceuticals USA
Active, not recruiting - verified March 2012
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Other: Decision aid exposure
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Ontario Ministry of Health and Long Term Care; Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified July 2011
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy

Condition: Lung Cancer
Interventions: Drug: MET/VEGFR2 inhibitor Foretinib; Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified March 2012
Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Condition: Astrocytic Tumors
Intervention: Drug: XL184
Sponsors: Exelixis; Exelixis
Active, not recruiting - verified June 2011
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

Conditions: Breast Cancer; Colon Cancer; Ovarian Cancer; Endometrium Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Facilitating Physical Activity Behavior and Health Outcomes in Breast Cancer Patients Receiving Chemotherapy

Condition: Breast Cancer
Interventions: Behavioral: Physical Activity Resource Kit; Behavioral: Standard Materials
Sponsors: Athabasca University; Athabasca University; University of Alberta; University of Calgary; Alberta Health Services
Recruiting - verified January 2010
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
The Effect of Soy Protein on Post- Breast Cancer Surgery Pain

Conditions: Pain; Chronic Disease; Breast Cancer
Interventions: Dietary Supplement: Isolated soy protein; Dietary Supplement: Isolated milk protein
Sponsors: McGill University Health Center; McGill University Health Center; National Cancer Institute (NCI); Louise & Alan Edwards Foundation; Alan Edwards Centre for Research on Pain
Suspended - verified January 2012
Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients

Condition: NON-SMALL CELL LUNG CANCER
Interventions: Dietary Supplement: IMN1207; Dietary Supplement: Casein
Sponsors: Immunotec Inc.; Immunotec Inc.
Active, not recruiting - verified June 2011
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Condition: Gastro-Intestinal Cancer
Interventions: Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan; Drug: Brivanib; Drug: Brivanib; Drug: Brivanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified February 2012
Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL

Conditions: Oral Cancer; High-grade Precancer
Interventions: Procedure: Fluorescence visualization device; Procedure: Fluorescence visualization device
Sponsors: University of British Columbia; University of British Columbia; Terry Fox Research Institute; British Columbia Cancer Agency
Recruiting - verified December 2011
Breast Lymph Node Mapping

Condition: Breast Cancer
Interventions: Other: Isosulfan Blue (Patent Blue Dye V); Other: Isosulfan Blue (Patent Blue Dye V)
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified April 2012
Endobronchial Ultrasound (EBUS) for Nodal Staging in Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Procedure: Endoscopic Ultrasound (EUS); Procedure: Endobronchial Ultrasound (EBUS)
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); C.E.T.O.C. - CHUM Endoscopic Tracheobronchial and Oesophageal Center; Marcel and Rolande Gosselin Chair in Thoracic Surgical Oncology; Fonds de la Recherche en Santé du Québec; Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Completed - verified November 2011
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma

Condition: Uveal Melanoma
Intervention: Drug: CP-675,206
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified September 2011
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cervical Cancer That Cannot Be Removed By Surgery

Condition: Cervical Cancer
Interventions: Drug: temsirolimus; Genetic: promoter methylation analysis; Genetic: fluorescence in situ hybridization; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified October 2011
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: capecitabine [Xeloda]; Drug: capecitabine [Xeloda]; Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab

Condition: Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)
Interventions: Procedure: Cardiac MRI; Biological: Biomarker Testing
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; Hoffmann-La Roche
Recruiting - verified August 2011
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
Abiraterone Acetate Plus Prednisone Drug-Drug Interaction With Dextromethorphan and Theophylline Treating Metastatic Castration-Resistant Prostate Cancer

Condition: Metastatic Castration-Resistant Prostate Cancer
Intervention: Drug: dextromethorphan hydrobromide or theophylline
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Active, not recruiting - verified August 2010
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: BIBF 1120; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified May 2012
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Condition: Brain Cancer
Intervention: Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Children's Healthcare of Atlanta; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; Phoenix Children's Hospital; Alberta Children's Hospital; University of Colorado, Denver; Seattle Children's Hospital; Johns Hopkins University; Children's Mercy Hospital-Kansas City, MO; MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children
Recruiting - verified March 2012
Minimally Invasive, Diagnosis and Staging of Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: Cervical Mediastinoscopy; Procedure: Endobronchial Ultrasound (EBUS); Procedure: Endoscopic Ultrasound (EUS)
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Fonds de la Recherche en Santé du Québec; Society of University Surgeons; Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified November 2011
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer

Condition: Lung Cancer
Interventions: Drug: PF-00299804; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Condition: Malignant Melanoma
Interventions: Drug: Vemurafenib; Drug: Dacarbazine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified October 2011
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Conditions: Advanced Solid Tumors With FGFR1 Amplication,; Advanced Solid Tumors With FGFR2 Amplication,; Advanced Solid Tumors With FGFR3 Mutation
Intervention: Drug: BGJ398
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab (Erbitux); Drug: Panitumumab (Vectibix)
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Conditions: Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent; Carcinoma; Hepatocellular; Liver Diseases; Neoplasms by Histologic Type
Interventions: Drug: ABT-869; Drug: Sorafenib
Sponsors: Abbott; Abbott
Active, not recruiting - verified March 2012
Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Metastatic Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Grupo Español de Investigación en Cáncer de Ovario; Cancer Research UK; Southwestern Oncology Group (SWOG)
Recruiting - verified March 2012
Eligard Observational Registry for Patients With Prostate Cancer

Condition: Cancer of the Prostate
Intervention:
Sponsors: CMX Research; CMX Research; Sanofi-Aventis
Active, not recruiting - verified May 2011
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: bortezomib; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified March 2011
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

Conditions: Hematologic Malignancy; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Hodgkin's Disease
Intervention: Drug: Ciclopirox Olamine
Sponsors: University Health Network, Toronto; University Health Network, Toronto; The Leukemia and Lymphoma Society
Recruiting - verified April 2012
Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Intervention: Other: Needle core biopsies of liver metastasis
Sponsors: Jewish General Hospital; Jewish General Hospital; Quebec Clinical Research Organization in Cancer; Fonds de la Recherche en Santé du Québec
Recruiting - verified September 2011
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified October 2011
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Condition: Non Small Cell Lung Cancer
Interventions: Biological: necitumumab; Drug: gemcitabine; Drug: cisplatin
Sponsors: ImClone LLC; ImClone LLC; Parexel; PPD; Medidata Solutions; Laboratory Corporation of America; University of Colorado, Denver; Thermo Fisher Scientific; ICON Clinical Research
Active, not recruiting - verified April 2012
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: docetaxel; Drug: FEC: 5-Fluorouracil/epirubicin/cyclophosphamide; Drug: carboplatin; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.
Active, not recruiting - verified May 2012
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Condition: Non Small Cell Lung Cancer
Interventions: Drug: pemetrexed; Drug: cisplatin; Biological: IMC-11F8
Sponsors: ImClone LLC; ImClone LLC; Quintiles; Parexel; PPD; Medidata Solutions; Laboratory Corporation of America; University of Colorado, Denver; Thermo Fisher Scientific
Active, not recruiting - verified April 2012
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Interventions: Drug: figitumumab; Drug: Cisplatin (Or Carboplatin); Drug: Etoposide; Drug: Cisplatin (Or Carboplatin); Drug: Etoposide
Sponsors: Pfizer; Pfizer
Terminated - verified May 2012
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Conditions: Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma
Interventions: Drug: figitumumab; Drug: pegvisomant
Sponsors: Pfizer; Pfizer
Terminated - verified May 2012
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Her2+; Advanced Metastatic Breast Cancer; Metastatic ErbB2; Invasive Breast Cancer; Advanced Breast Cancer; Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Conditions: Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders
Intervention: Biological: Donor lymphocyte preparation depleted of host functional alloreactive T-cells
Sponsors: Kiadis Pharma; Kiadis Pharma
Suspended - verified April 2012
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Metabolism of Lipids in Advanced Cancer

Conditions: Lung Neoplasms; Cachexia
Interventions: Other: Blood draws; Biological: Oral administration of stable isotope (deuterium); Procedure: Metabolic rate testing
Sponsors: Alberta Health Services; Alberta Health Services
Terminated - verified April 2012
Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012
A Study for Treatment of Superficial Bladder Cancer Using OGX-427

Condition: Bladder Cancer
Intervention: Drug: OGX-427
Sponsors: Vancouver Coastal Health; Vancouver Coastal Health; NCIC Clinical Trials Group; Vancouver General Hospital Foundation
Recruiting - verified February 2012
A Study to Compare Subcutaneous Versus Intravenous Administration of Herceptin (Trastuzumab) in Women With HER2Positive Early Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: 5-fluorouracil; Drug: epirubicin; Drug: cyclophosphamide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified December 2011
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Conditions: Pancreatic Neoplasm; Pituitary Neoplasm; Nelson Syndrome; Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: Cisplatin; Drug: Pemetrexed
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified May 2012
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

Condition: Cancer
Intervention: Drug: dalteparin
Sponsors: Eisai Inc.; Eisai Inc.
Active, not recruiting - verified April 2012
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of Avastin (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma

Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: temozolomide; Radiation: Radiation therapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Trial of Degarelix in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Zoladex
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Completed - verified March 2012
Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Conditions: Prostate Cancer; Sexual Dysfunction
Interventions: Drug: tadalafil; Other: placebo
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified February 2012
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects

Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

Condition: Metastatic Colorectal Cancer
Intervention: Drug: EZN-2208, Cetuximab and Irinotecan
Sponsors: Enzon Pharmaceuticals, Inc.; Enzon Pharmaceuticals, Inc.
Active, not recruiting - verified September 2011
Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain

Conditions: Nausea and Vomiting; Pain; Sleep Disorders; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: methadone hydrochloride; Other: questionnaire administration; Procedure: management of therapy complications
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Terminated - verified July 2011
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Sirolimus (Rapamune); Drug: Cyclosporin (Neoral) or Tacrolimus (Prograf)
Sponsors: St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton
Withdrawn - verified March 2012
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Interventions: Drug: BMS-833923; Drug: Carboplatin; Drug: Etoposide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

Conditions: Solid Tumors and Lymphoma; Cancer
Intervention: Drug: GSK2141795
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

Conditions: Breast Cancer; Advanced Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Active, not recruiting - verified May 2012
Prophylactic Cranial Irradiation in Patients With HER-2-Positive Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: Prophylactic Cranial Irradiation
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified August 2011
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Conditions: Colorectal Cancer; Head and Neck Cancer; Neoplasm Metastasis
Interventions: Drug: BMS-754807; Drug: cetuximab (Erbitux®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer

Conditions: Breast Cancer; Invasive Breast Cancer
Intervention: Procedure: Sentinel Lymph Node Biopsy
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Fondation du cancer du sein du Québec
Recruiting - verified June 2011
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial

Condition: Esophageal Neoplasms
Interventions: Other: Preoperative treatment of chemotherapy and radiation; Other: Postoperative treatment of chemotherapy and radiation
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Recruiting - verified June 2011
Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Conditions: Neoplasms; Breast Neoplasms; Breast Cancer
Interventions: Drug: AZD8931; Drug: Paclitaxel; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified February 2012
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

Conditions: Carcinoma, Pancreatic Ductal; Pancreatic Cancer; Pancreatic Disease
Interventions: Biological: AGS-1C4D4; Biological: Gemcitabine
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Agensys, Inc.
Active, not recruiting - verified March 2012
Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer

Conditions: Lung Neoplasm; Small Cell Carcinoma
Intervention: Radiation: Hypofractionated Chest Radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified September 2011
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial)

Conditions: Cervical Cancer; Squamous Cell Carcinoma; Adenosquamous Carcinoma; Adenocarcinoma
Interventions: Procedure: CT Abdomen and Pelvis scan + whole body PET-CT scan; Procedure: CT Abdomen and Pelvis scan
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Recruiting - verified June 2011
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Clinical and Biologic Effects of Metformin in Early Stage Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Metformin
Sponsors: Mount Sinai Hospital, Canada; Mount Sinai Hospital, Canada; Princess Margaret Hospital, Canada
Completed - verified January 2012
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients

Condition: Non Small Cell Lung Cancer
Interventions: Drug: AZD6244; Drug: docetaxel; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Completed - verified March 2012
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Intervention: Radiation: Stereotactic Radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate plus prednisone/prednisolone; Drug: placebo plus prednisone/prednisolone
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Active, not recruiting - verified May 2010
Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer

Condition: Epithelial Ovarian Cancer
Intervention: Drug: Intraperitoneal (IP) Cisplatin
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Terminated - verified October 2011
ARI103094-Follow-Up Study for REDUCE Study Subjects

Conditions: Neoplasms, Prostate; Prostate Cancer; Benign Prostatic Hyperplasia
Intervention: Other: observational
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Active, not recruiting - verified May 2012
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)

Condition: Advanced Gastric Cancer
Interventions: Drug: Everolimus; Drug: everolimus placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012
A Study of Pre-operative Metformin in Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Metformin
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Jewish General Hospital
Active, not recruiting - verified July 2009
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Condition: Advanced Solid Malignancies
Intervention: Drug: HSP990
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Conditions: Solid Tumors; Ovarian Cancer
Interventions: Drug: OSI-906; Drug: Paclitaxel
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases

Condition: Metastatic Non-Small Cell Lung Cancer
Intervention: Drug: nimotuzumab
Sponsors: YM BioSciences; YM BioSciences; CIMYM BioSciences
Terminated - verified June 2011
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: anti-IGF-1R recombinant monoclonal antibody MK-0646; Drug: cisplatin; Drug: etoposide; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified June 2011
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified May 2012
A Study of IMC-1121B in Colorectal Cancer

Condition: Colorectal Carcinoma
Interventions: Biological: IMC-1121B (ramucirumab); Drug: Oxaliplatin; Drug: Folinic acid; Drug: 5-FU; Drug: 5-FU
Sponsors: ImClone LLC; ImClone LLC
Completed - verified November 2011
Pilot Study of Colon Cancer Screening Tests

Conditions: Colorectal Cancer; Colon Cancer; Adenomatous Polyps
Interventions: Other: Fecal occult blood test; Procedure: Virtual colonoscopy; Procedure: Optical colonoscopy
Sponsors: McMaster University; Hamilton Health Sciences Corporation; McMaster University
Terminated - verified January 2012
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Celgene Corporation; Celgene Corporation; University of Arizona
Active, not recruiting - verified May 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
CT-Based Versus Conventional Simulation for Palliative Radiotherapy of Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Intervention: Procedure: CT- simulation scan
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified August 2011
Biomarker - Panitumumab Response With KRAS Wild Type MCC

Condition: Metastatic Colorectal Cancer
Intervention: Drug: Panitumumab
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Active, not recruiting - verified February 2012
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1

Condition: Prostate Cancer
Intervention: Biological: DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
Sponsors: McMaster University; Hamilton Health Sciences Corporation
Recruiting - verified December 2011
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsors: Morphotek; Morphotek
Active, not recruiting - verified March 2012
Treatment With Pazopanib for Neoadjuvant Breast Cancer

Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: doxorubicin + cyclophosphamide; Drug: paclitaxel + pazopanib; Procedure: surgery; Drug: pazopanib monotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting - verified April 2012
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Albumin-bound paclitaxel (ABI-007)/Gemcitabine; Drug: Gemcitabine
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified May 2012
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Active, not recruiting - verified August 2011
Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer

Conditions: Cancer of the Prostate; Prostate Cancer; Prostatic Neoplasms
Interventions: Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E; Drug: Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified September 2011
MTD, Safety, and Efficacy of CC-4047 Alone With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: CC-4047; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified March 2012
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
A Comparison of Contrast Enhanced Ultrasound (CEUS) and Contrast Enhanced Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) for Characterization of Focal Liver Masses

Condition: Liver Tumors
Intervention:
Sponsors: Foothills Medical Centre; Foothills Medical Centre; Vancouver General Hospital; London Health Sciences Centre; Centre Hospitalier de l'Université de Montréal
Recruiting - verified March 2012
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Condition: Liver Cancer
Interventions: Drug: Brivanib; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified March 2011
Health-Related Quality of Life in Gay Men With Localized Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Active, not recruiting - verified November 2011
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: pemetrexed; Drug: pemetrexed; Drug: BI 6727
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified May 2012
Pilot Project: Fast Whole-body Spect Scanning to Improve the Detection of Bone Metastases in Patients With Diagnosed Cancer

Condition: Bone Metastases
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Suspended - verified June 2011
Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified November 2011
Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Conditions: Anxiety Disorder; Cognitive/Functional Effects; Colorectal Cancer; Depression; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Behavioral: exercise intervention; Other: counseling intervention; Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: fatigue assessment and management; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012
A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Intervention: Drug: Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen with Avastin (Bevacizumab)
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Hoffmann-La Roche; Pfizer; Sanofi-Aventis; Ottawa Regional Cancer Foundation
Active, not recruiting - verified July 2011
Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Fulvestrant + ZACTIMA; Drug: Fulvestrant + Placebo
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); AstraZeneca
Active, not recruiting - verified October 2011
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Conditions: Neoplasms, Breast; Advanced or Metastatic ErbB2-overexpressing Breast Cancer
Intervention: Drug: Lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma

Conditions: Brain Cancer; Cancer; Solid Tumor; Lymphoma
Intervention: Biological: 18F-FLT
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified March 2012
The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors

Condition: Colonic Neoplasms
Interventions: Behavioral: Exercise Training; Other: Usual Care
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy

Condition: Pancreatic Cancer
Intervention: Drug: Pentamidine
Sponsors: Oncozyme Pharma Inc.; Oncozyme Pharma Inc.
Completed - verified June 2011
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: BIBF1120 plus pemetrexed; Drug: Placebo plus pemetrexed; Drug: Folic Acid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified May 2012
A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment

Condition: Colorectal Cancer
Intervention: Drug: pentamidine
Sponsors: Oncozyme Pharma Inc.; Oncozyme Pharma Inc.
Completed - verified June 2011
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Conditions: Skin Cancer; Melanoma; Metastatic Melanoma
Interventions: Drug: temozolomide; Drug: ABT-888; Drug: Placebo
Sponsors: Abbott; Abbott
Active, not recruiting - verified March 2012
MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer Followed by Radical Prostatectomy

Condition: Prostate Neoplasm
Intervention: Procedure: Focal Phothtermal Ablation
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Completed - verified December 2008
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cediranib maleate; Drug: paclitaxel; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified March 2012
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Condition: Advanced Cancer
Interventions: Drug: Capecitabine; Drug: Doxorubicin; Drug: Ixabepilone; Drug: Docetaxel; Drug: Paclitaxel; Drug: Brivanib alaninate
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Conditions: Melanoma; Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

Condition: Ovarian Neoplasms
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Bayer
Active, not recruiting - verified April 2012
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Conditions: Advanced Solid Tumors; Metastatic Solid Tumors
Interventions: Drug: BMS-754807; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified February 2012
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Conditions: Solid Tumors; Neoplasms, Breast; Cancer
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors

Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Amgen; Amgen
Active, not recruiting - verified January 2012
Phase III, Open-label Study of Nilotinib Versus Imatinib in GIST Patients

Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified October 2011
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: trastuzumab (Herceptin®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2010
A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy

Condition: Locally Advanced Breast Cancer
Intervention:
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Juravinski Cancer Centre Foundation
Completed - verified October 2011
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Conditions: Lung Cancer; Precancerous Condition
Interventions: Dietary Supplement: inositol; Other: placebo
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2009
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Condition: Advanced Breast Cancer
Interventions: Drug: Bosutinib; Drug: Exemestane
Sponsors: Pfizer; Pfizer
Terminated - verified March 2012
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib; Drug: Capecitabine
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Active, not recruiting - verified May 2012
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: R1507; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Terminated - verified August 2011
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma

Condition: Recurrent Glioblastoma
Interventions: Drug: Cediranib; Drug: Cediranib; Drug: Lomustine Chemotherapy
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified June 2011
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Intervention: Drug: sorafenib + FOLFIRI
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Bayer
Active, not recruiting - verified October 2011
A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsors: USHIFU, LLC; USHIFU, LLC
Recruiting - verified April 2012
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies

Condition: Cancer
Intervention: Drug: P1446A-05
Sponsors: Piramal Healthcare Limited; Piramal Healthcare Limited
Active, not recruiting - verified June 2011
Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: ridaforolimus; Genetic: gene expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Condition: Head and Neck Neoplasms
Intervention: Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012
Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy

Conditions: Lung Neoplasm; Cell Hypoxia
Interventions: Other: 18F-FAZA; Other: 18F-Fluorodeoxyglucose (18F-FDG)
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Conditions: Anaplastic Astrocytoma; Glioblastoma
Interventions: Drug: trabedersen; Drug: temozolomide or carmustine for infusion or lomustine; Device: Drug delivery system for administration of AP 12009; Procedure: Placement of Drug Delivery System
Sponsors: Antisense Pharma; Antisense Pharma
Terminated - verified March 2012
Letrozole in Treating Women With Primary Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy

Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwestern Oncology Group (SWOG); Cancer and Leukemia Group B
Active, not recruiting - verified May 2012
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012
Screening Methods in Finding Lung Cancer Early in Current or Former Smokers

Conditions: Lung Cancer; Tobacco Use Disorder
Interventions: Other: laboratory biomarker analysis; Other: screening questionnaire administration; Procedure: bronchoscopic and lung imaging studies; Procedure: computed tomography; Procedure: endoscopic biopsy; Procedure: quality-of-life assessment
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Active, not recruiting - verified March 2012
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: AZD2281; Drug: matching placebo
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified October 2011
Magnetic Resonance (MR) Spectroscopy in Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: 3T MR Spectroscopy
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg

Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Terminated - verified May 2012
Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca

Conditions: Locally Advanced Breast Cancer; Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified September 2011
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Condition: Solid Tumors
Intervention: Drug: cediranib
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: Placebo + Docetaxel/Prednisone; Drug: Dasatinib + Docetaxel/Prednisone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified February 2012
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Condition: Hematologic Cancer
Intervention: Biological: elotuzumab (HuLuc63)
Sponsors: Abbott; Abbott; Bristol-Myers Squibb
Active, not recruiting - verified December 2011
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Condition: Non Small Cell Lung Cancer
Interventions: Drug: BMS-690514; Drug: Erlotinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified February 2012
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: ASA404; Drug: Placebo; Drug: docetaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Terminated - verified May 2012
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Condition: Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: zoledronic acid; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified August 2011
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsors: Morphotek; Morphotek
Terminated - verified April 2012
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Conditions: Advanced Cancer; Metastatic Cancer; Lymphoma; Solid Tumors; Advanced Malignancies
Intervention: Drug: CPI-613
Sponsors: Cornerstone Pharmaceuticals, Inc.; Cornerstone Pharmaceuticals, Inc.
Active, not recruiting - verified January 2012
Platinum Resistant Ovarian Cancer Evaluation of Doxil and EC145 Combination Therapy

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: pegylated liposomal doxorubicin (PLD); Drug: EC20; Drug: EC20
Sponsors: Endocyte; Endocyte
Active, not recruiting - verified March 2012
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

Condition: Glioma
Interventions: Drug: BIBW 2992; Drug: TMZ; Drug: BIBW 2992 plus TMZ
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Completed - verified January 2012
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
SPECT-CT Guided Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) in Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: SPECT/CT guided LM/SL
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; London Regional Cancer Program, Canada; University of Western Ontario, Canada
Terminated - verified March 2012
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma; Carcinoma, Renal Cell
Interventions: Drug: Pazopanib; Drug: Sunitinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients

Condition: Prostate Cancer
Intervention: Drug: Docetaxel
Sponsors: Centre hospitalier universitaire de Québec; Centre hospitalier universitaire de Québec
Terminated - verified February 2012
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsors: Agennix; Agennix
Active, not recruiting - verified August 2011
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Conditions: Advanced Colorectal Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum
Interventions: Drug: ABT-869; Drug: bevacizumab; Drug: oxaliplatin; Drug: folinic acid; Drug: fluorouracil; Drug: ABT-869
Sponsors: Abbott; Abbott; Genentech
Active, not recruiting - verified March 2012
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsors: Exelixis; Exelixis
Active, not recruiting - verified June 2011
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Condition: Breast Cancer
Interventions: Biological: ramucirumab (IMC-1121B); Drug: docetaxel; Other: placebo
Sponsors: ImClone LLC; ImClone LLC
Active, not recruiting - verified January 2012
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Conditions: Breast Cancer; Triple Negative Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: AZD2281; Drug: Paclitaxel
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012
A Phase III Study of Alpharadin (Radium-223)in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsors: Algeta ASA; Algeta ASA; Bayer
Active, not recruiting - verified September 2011
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

Conditions: Testicular Cancer; Seminoma; Non-seminomatous
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified August 2011
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Carboplatin-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Condition: Carcinoma, Hepatocellular
Interventions: Drug: sunitinib malate; Drug: sorafenib
Sponsors: Pfizer; Pfizer
Terminated - verified January 2012
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Bayer
Active, not recruiting - verified May 2012
Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer And Who Are Receiving Exemestane on Clinical Trial CAN-NCIC-MAP3

Conditions: Breast Cancer; Osteoporosis
Interventions: Other: biologic sample preservation procedure; Other: physiologic testing; Procedure: dual x-ray absorptometry
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified August 2011
Monitoring of Breast Tissue Change Due to Hormone Replacement Therapy in Post-menopausal Women Using OBS

Condition: Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; St. Michael's Hospital, Toronto
Not yet recruiting - verified November 2008
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide and low-dose dexamethasone; Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles; Drug: Melphalan, Prednisone and Thalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified April 2011
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study

Conditions: Non-small Cell Lung Cancer; Breast Cancer; Head and Neck Cancer; Ovarian Cancer; Esophageal Cancer; Lymphoma
Intervention: Other: PET/CT scan
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Active, not recruiting - verified February 2012
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Condition: Extensive-stage Small Cell Lung Cancer
Interventions: Drug: Obatoclax; Drug: Obatoclax; Drug: Obatoclax; Drug: Carboplatin and etoposide
Sponsors: Gemin X; Gemin X; Cephalon
Completed - verified January 2012
Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Condition: Transitional Cell Carcinoma
Intervention: Drug: Paclitaxel
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Celgene Corporation
Recruiting - verified July 2011
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Conditions: or Gastro-esophageal Junction Adenocarcinoma That is Unresectable Due to Locally Advanced Metastatic, or Locally Recurrent Disease.; ErbB2 (HER2) Amplified Gastric; Neoplasms, Gastrointestinal Tract; Esophageal
Interventions: Drug: Lapatinib; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Conditions: Ovarian Carcinoma; Breast Cancer
Intervention: Drug: AZD2281
Sponsors: AstraZeneca; AstraZeneca; British Columbia Cancer Agency
Active, not recruiting - verified March 2012
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified December 2010
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012
Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone

Conditions: Cancer; GCT; Giant Cell Tumor of Bone; Benign GCT
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Condition: Renal Cell Carcinoma
Intervention: Biological: AGS-003+sunitinib
Sponsors: Argos Therapeutics; Argos Therapeutics
Active, not recruiting - verified January 2012
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsors: Pfizer; Pfizer
Terminated - verified January 2012
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Conditions: Prevention of Venous Thromboembolism; Cancer
Interventions: Drug: Semuloparin sodium (AVE5026); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified December 2011
Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)

Condition: Breast Cancer
Intervention: Other: Cardio-vascular MRI
Sponsors: University of Calgary; University of Calgary
Terminated - verified October 2011
Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer

Conditions: Breast Cancer; Estrogen Receptor-Positive Breast Cancer; Breast Cancer, Estrogen Receptor-Positive; ER+ Breast Cancer
Interventions: Drug: entinostat; Drug: exemestane
Sponsors: Syndax Pharmaceuticals; Syndax Pharmaceuticals
Active, not recruiting - verified April 2012
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012
Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers

Condition: Prostate Cancer
Interventions: Procedure: 3T MR Imaging; Procedure: C-Choline PET Scanning; Procedure: Gene Rearrangement
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Conditions: Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Adenosquamous Cell
Interventions: Drug: CP 751,871 (Figitumumab); Drug: Erlotinib; Drug: Erlotinib
Sponsors: Pfizer; Pfizer
Terminated - verified April 2012
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: daunorubicin hydrochloride; Other: pharmacological study; Procedure: dual x-ray absorptometry
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified October 2011
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; GlaxoSmithKline
Active, not recruiting - verified May 2012
Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality

Condition: Non Small Cell Lung Cancer
Interventions: Dietary Supplement: melatonin; Dietary Supplement: placebo
Sponsors: The Canadian College of Naturopathic Medicine; The Canadian College of Naturopathic Medicine; The Ottawa Hospital
Recruiting - verified February 2012
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Conditions: Hedgehog Pathway; Smoothened; Basal Cell Carcinoma (BCC); Basal Cell Nevoid Syndrome (BCNS)
Intervention: Drug: BMS-833923 (XL139)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified August 2011
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: ASA404; Drug: Placebo; Drug: carboplatin; Drug: Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Terminated - verified May 2012
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: LBH589 (i.v. panobinostat)
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012
Palliative Radiotherapy and Brachytherapy for Oesophageal Cancer Dysphagia

Condition: Esophageal Cancer
Interventions: Radiation: Protracted Course Radiotherapy; Radiation: Short Course Radiotherapy
Sponsors: International Atomic Energy Agency; International Atomic Energy Agency
Completed - verified October 2011
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Conditions: Head and Neck Cancer; Xerostomia
Interventions: Drug: pilocarpine hydrochloride; Procedure: acupuncture-like transcutaneous electrical nerve stimulation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified December 2011
Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Condition: Metastatic Renal Cell Cancer
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
No longer available - verified August 2011
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Conditions: Breast Cancer; Endometrial Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: metformin hydrochloride; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); London Regional Cancer Program at London Health Sciences Centre
Completed - verified August 2010
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBW 2992; Drug: placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Completed - verified January 2012
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
PET/CT: Role in Detecting Unknown Primary Head and Neck Cancer

Condition: Head and Neck Cancer
Intervention: Other: PET/CT
Sponsors: University of Calgary; University of Calgary; Tom Baker Cancer Centre
Completed - verified April 2008
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: erlotinib [Tarceva]; Drug: gemcitabine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Condition: Cancer
Intervention: Drug: ARRY-380, HER2 inhibitor; oral
Sponsors: Array BioPharma; Array BioPharma
Active, not recruiting - verified February 2012
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: brivanib alaninate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012
Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

Conditions: Metastatic ErbB2; Neoplasms, Breast; Breast Cancer
Interventions: Drug: lapatinib; Drug: Digoxin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Conditions: Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Neoplasm Metastasis; Brain Neoplasms
Interventions: Drug: ABT-888; Radiation: Whole Brain Radiation Therapy
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)

Condition: Solid Tumors
Interventions: Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin; Drug: MK1775; Drug: MK1775; Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms

Conditions: Head and Neck Neoplasm; Prostatic Neoplasm; Pancreatic Neoplasm
Interventions: Drug: PF00562271; Drug: PF00562271; Drug: PF00562271; Drug: PF00562271
Sponsors: Pfizer; Pfizer
Completed - verified March 2012
Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer

Condition: Extensive Stage Small Cel Lung Cancer
Intervention: Radiation: thoracic radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified April 2012
Quantifying Lung Tumor Movement Under Deep Inspiration Breath Holds

Condition: Lung Cancer
Intervention: Other: CT scan of the chest under deep inspiration breath hold
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified August 2011
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Condition: Prostatic Neoplasms
Interventions: Drug: placebo plus prednisone/prednisolone; Drug: abiraterone acetate plus prednisone/prednisolone
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Active, not recruiting - verified August 2011
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Conditions: Advanced Non-small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified October 2011
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

Conditions: Renal Cell Carcinoma; Kidney Cancer; Urogenital Cancer
Interventions: Drug: Bevacizumab + Temsirolimus; Drug: Bevacizumab + Interferon-Alfa
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Condition: Breast Cancer
Interventions: Drug: Docetaxel; Drug: Trastuzumab; Drug: Carboplatin; Drug: Bevacizumab; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Cancer International Research Group; Hoffmann-La Roche; Genentech
Active, not recruiting - verified December 2011
A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Conditions: Breast Cancer; Breast Tumors; Metastatic Cancer
Interventions: Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant
Sponsors: Amgen; Amgen
Completed - verified January 2012
Bone Health Observational Study

Condition: Prostate Cancer
Intervention:
Sponsors: CMX Research; CMX Research; AstraZeneca
Active, not recruiting - verified May 2011
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

Condition: Urinary Bladder Neoplasms
Interventions: Drug: larotaxel (XRP9881); Drug: gemcitabine; Drug: cisplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified September 2011
Sorafenib Long Term Extension Program (STEP)

Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer; ICON Clinical Research
Recruiting - verified May 2012
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

Condition: Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Biological: aflibercept
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

Condition: Hematologic Neoplasms
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified October 2011
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Conditions: Melanoma; Lung Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics
Completed - verified March 2012
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified November 2009
A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer

Conditions: Radiotherapy Induced Mucositis; Head and Neck Cancer
Interventions: Dietary Supplement: manuka honey; Dietary Supplement: placebo gel
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Completed - verified November 2011
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

Condition: Colorectal Neoplasms
Interventions: Drug: Bevacizumab (avastin); Drug: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]); Drug: AG-013736 (axitinib); Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]); Drug: AG-013736 (axitinib); Drug: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]); Drug: Bevacizumab (avastin); Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Sponsors: Pfizer; Pfizer
Completed - verified April 2012
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsors: AstraZeneca; AstraZeneca
Completed - verified July 2011
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor

Conditions: Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: cixutumumab; Genetic: protein expression analysis; Genetic: western blotting; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

Conditions: Ovarian Neoplasms; Ovarian Cancer
Interventions: Drug: AZD0530; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: AstraZeneca; AstraZeneca
Completed - verified February 2012
A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

Conditions: Ovarian Cancer; Endometrial Cancer
Intervention: Drug: MKC-1
Sponsors: EntreMed; EntreMed
Completed - verified January 2012
Laparoscopic Approach to Cervical Cancer

Condition: Cervical Cancer
Interventions: Procedure: Total Abdominal Radical Hysterectomy; Procedure: Total Laparoscopic or Robotic Radical Hysterectomy
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; M.D. Anderson Cancer Center
Recruiting - verified June 2011
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer

Condition: Nasopharyngeal Cancer
Interventions: Drug: Gemcitabine; Drug: Carboplatin/Cisplatin; Drug: erlotinib
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Hoffmann-La Roche
Completed - verified October 2011
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Conditions: Solid Tumors; Breast Cancer; Cowden Syndrome
Intervention: Drug: BGT226
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012
Bone Health in Gynecologic Cancers-does FOSAVANCE Help?

Condition: Ovarian Cancer
Interventions: Drug: placebo; Drug: alendronate/cholecalciferol
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Completed - verified June 2011
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Conditions: Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 (Figitumumab); Drug: Carboplatin; Drug: Paclitaxel; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Pfizer; Pfizer
Terminated - verified April 2012
SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial

Conditions: Urothelial Cancer; Bladder Cancer; Adult
Interventions: Drug: SU011248; Drug: Placebo
Sponsors: Alberta Health Services; Alberta Health Services; Pfizer
Active, not recruiting - verified September 2011
Do Skin Markings Reflect the Location of the Surgical Cavity During Daily Radiotherapy Treatment?

Condition: Breast Cancer
Intervention:
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Completed - verified June 2011
GAUSS: A Study of RO5072759 in Patients With Indolent Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: MORAb-009; Drug: Placebo; Drug: Gemcitabine
Sponsors: Morphotek; Morphotek
Completed - verified February 2012
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

Condition: Pancreatic Neoplasm
Interventions: Drug: placebo; Drug: Aflibercept (AVE0005)
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Terminated - verified July 2011
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012
Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum

Conditions: Lung Cancer; Tobacco Use Disorder
Interventions: Drug: defined green tea catechin extract; Other: placebo
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; National Cancer Institute (NCI); University of Cincinnati
Completed - verified March 2012
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed on or After Trastuzumab

Condition: Breast Cancer
Intervention: Drug: panobinostat, trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012
Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Bortezomib
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada; Ortho Biotech, Inc.
Recruiting - verified October 2011
Studying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and Formoterol

Conditions: Lung Cancer; Precancerous Condition
Interventions: Drug: budesonide/formoterol fumarate dihydrate inhalation aerosol; Genetic: DNA methylation analysis; Genetic: comparative genomic hybridization; Genetic: microarray analysis; Other: bronchoalveolar lavage; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; Astra Zeneca Canada
Completed - verified March 2012
Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

Conditions: Cancer; Liver Cancer; Primary Liver Cancer; Hepatocellular Carcinoma; Hepatoma
Interventions: Drug: PI-88; Drug: placebo
Sponsors: Progen Pharmaceuticals; Progen Pharmaceuticals
Terminated - verified June 2011
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: melphalan; Drug: thiotepa
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified February 2012
Panitumumab DDI Irinotecan

Condition: Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Irinotecan
Sponsors: Amgen; Amgen
Completed - verified July 2011
Efficacy Study of ABR-215050 to Treat Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: ABR-215050, tasquinimod; Drug: Placebo
Sponsors: Active Biotech AB; Active Biotech AB
Active, not recruiting - verified December 2011
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

Conditions: Breast Cancer; Prostate Cancer; Bone Neoplasms
Interventions: Drug: AZD0530; Drug: Zoledronic Acid
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Alimta or Taxotere
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified February 2012
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: CP-675,206 and gemcitabine
Sponsors: Pfizer; Pfizer
Completed - verified August 2011
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib; Drug: Pazopanib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

Condition: Prostate Cancer
Interventions: Drug: ZD4054; Other: Best supportive care
Sponsors: AstraZeneca; AstraZeneca
Completed - verified March 2012
Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Dutasteride
Sponsors: Canadian Urology Research Consortium; Canadian Urology Research Consortium; GlaxoSmithKline
Active, not recruiting - verified December 2011
Sutent Maintenance After Response to Taxotere

Conditions: Prostate Cancer; Hormone Refractory
Intervention: Drug: Sunitinib (SU011248)
Sponsors: Alberta Health Services; Alberta Health Services; Pfizer
Active, not recruiting - verified September 2011
Pertuzumab and Cetuximab in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Cetuximab

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: pertuzumab; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; National Cancer Institute (NCI); Massachusetts General Hospital; Genentech
Active, not recruiting - verified February 2012
AMR PH GL 2007 CL 001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Condition: Small Cell Lung Cancer
Interventions: Drug: Amrubicin; Drug: Topotecan
Sponsors: Celgene Corporation; Celgene Corporation
Completed - verified July 2011
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: Herceptin; Drug: docetaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

Conditions: Cervical Cancer; Papillomavirus Infection
Intervention: Biological: GSK Bio's HPV vaccine 580299 (Cervarix TM)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified November 2011
Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)

Conditions: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009
Patients With Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Carcinoma
Interventions: Drug: ABI-007; Drug: Taxol
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified May 2012
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: irinotecan hydrochloride; Drug: olaparib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified February 2012
A Phase I/II Study to Determine the MTD and Safety of CC-4047 Administered in Conjunction With Cisplatin and Etoposide

Condition: Carcinoma, Small Cell
Intervention: Drug: Pomalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Completed - verified May 2011
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Active, not recruiting - verified November 2011
BEATRICE Study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard adjuvant chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified March 2012
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: LBH589
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012
Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed Phase 1; Drug: Cisplatin Phase 1; Procedure: Radiation Therapy; Drug: Pemetrexed Phase 2; Drug: Cisplatin Phase 2
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Active, not recruiting - verified August 2011
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.

Conditions: Palliative Care; Pain; Cancer
Interventions: Drug: Sativex Low Dose; Drug: Sativex Medium Dose; Drug: Sativex High Dose
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Quintiles
Completed - verified June 2011
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: carfilzomib
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Active, not recruiting - verified July 2011
Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy

Condition: Breast Cancer
Intervention: Procedure: Blood Test
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified January 2012
PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy

Condition: Squamous Cell Cancer
Intervention: Other: PET-CT
Sponsors: Alberta Health Services; Alberta Health Services; Calgary Health Region
Completed - verified August 2011
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

Conditions: Gastro Esophageal(GE)Junction Cancer; Neoplasms, Gastrointestinal Tract; Gastric Cancer
Intervention: Drug: Lapatinib and Capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified November 2011
Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer (NSCLC)
Intervention: Drug: ABT-869
Sponsors: Abbott; Abbott; Genentech
Active, not recruiting - verified March 2012
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Peritoneal Neoplasms
Intervention: Drug: Volociximab
Sponsors: Facet Biotech; Facet Biotech; Biogen Idec
Terminated - verified March 2012
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

Conditions: Prostatic Neoplasms; Neoplasm Metastasis
Interventions: Drug: Aflibercept (AVE0005); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified April 2012
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: recombinant human interleukin-21; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012
A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

Condition: Cancer of the Cervix
Interventions: Drug: Sorafenib; Drug: Cisplatin; Procedure: Radiation
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Bayer
Active, not recruiting - verified October 2011
Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: Helical tomotherapy IMRT
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Active, not recruiting - verified July 2007
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: HDAC inhibitor SB939; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: immunologic technique; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified June 2011
Observation or Radical Treatment in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Procedure: conventional surgery; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: external beam radiation therapy; Procedure: PSA tests; Procedure: Biopsies; Procedure: Rectal exam
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group; Radiation Therapy Oncology Group; Breast International Group
Terminated - verified August 2011
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012
Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS)

Condition: Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Mount Sinai Hospital, Canada; Hamilton Health Sciences Corporation
Recruiting - verified November 2008
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified July 2011
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer

Condition: Cervix Cancer
Interventions: Procedure: Cervical tissue biopsy analysis: Comet assay; Procedure: Biopsy: Measurement of histone gamma H2AX phosphorylation; Procedure: Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha; Procedure: Measurement of vascular perfusion: contrast enhanced MRI
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; Canadian Institutes of Health Research (CIHR)
Terminated - verified February 2012
Advanced Ovarian Cancer and Sexuality Phase 1

Conditions: Ovarian Cancer; Sexual Function
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Completed - verified November 2011
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Active, not recruiting - verified March 2012
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Xeloda
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Condition: Neoplasms
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsors: OncoGenex Technologies; OncoGenex Technologies
Active, not recruiting - verified December 2011
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Procedure: quality-of-life assessment; Radiation: Radiation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; European Organization for Research and Treatment of Cancer - EORTC; Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified March 2012
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Conditions: Tumor Antigen-positive Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: Bevacizumab; Drug: Irinotecan; Drug: Capecitabine
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Hoffmann-La Roche
Completed - verified March 2012
A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Ara-C (Cytarabine)
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Terminated - verified October 2011
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: Taxane (docetaxel or paclitaxel)
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Conditions: Bile Duct Neoplasms; Gallbladder Cancer
Intervention: Biological: Trastuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed - verified December 2011
Inflammatory Breast Cancer (IBC) Registry

Condition: Breast Cancer
Interventions: Other: Interview; Procedure: Blood and Tissue Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

Conditions: Neoplasms, Prostate; Prostate Cancer
Interventions: Drug: dutasteride; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

Condition: Renal Cell Carcinoma
Interventions: Drug: Sorafenib; Drug: temsirolimus (Torisel)
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: AG-013736; Drug: Gemcitabine; Drug: Gemcitabine; Drug: placebo
Sponsors: Pfizer; Pfizer
Completed - verified December 2011
Esomeprazole With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

Conditions: Esophageal Cancer; Precancerous Condition
Interventions: Drug: acetylsalicylic acid; Drug: esomeprazole magnesium; Other: placebo
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Completed - verified June 2010
Patient Satisfaction & Quality Of Life in Patients With Cervical Cancer

Conditions: Psychosocial; Cervical Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Active, not recruiting - verified March 2012
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Condition: Myelogenous Leukemia, Chronic
Interventions: Drug: nilotinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012
Aerobic Capacity and Body Composition in Colon Cancer Patients

Condition: Colonic Neoplasms
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified April 2012
Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: Carboplatin; Drug: irinotecan hydrochloride
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Completed - verified June 2011
Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)

Condition: Non Small Cell Lung Cancer
Intervention: Drug: Erlotinib
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Hoffmann-La Roche
Recruiting - verified December 2011
HPV Testing for Cervical Cancer Screening Study

Condition: Cervical Cancer Screening
Interventions: Procedure: Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive; Procedure: Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR)
Recruiting - verified March 2012
Extension to Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Drug: gimatecan
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Docetaxel; Drug: Trastuzumab; Drug: Bevacizumab
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; International Drug Development Institute (IDDI)
Active, not recruiting - verified September 2011
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: erlotinib; Drug: sunitinib; Drug: erlotinib; Drug: placebo
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012
First Line Therapy for Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: ABI-007
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified February 2011
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Condition: Non Small Cell Lung Cancer
Interventions: Drug: RAD001; Drug: erlotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

Conditions: Tumor Antigen-positive Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Biological: Immunotherapeutic GSK1572932A; Drug: Cisplatin (CDDP); Drug: Vinorelbine; Procedure: Radiotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified October 2011
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Drug: 5 fluorouracil; Drug: irinotecan; Drug: levo- leucovorin; Drug: sunitinib; Drug: 5 fluorouracil; Drug: irinotecan; Drug: levo- leucovorin; Drug: placebo
Sponsors: Pfizer; Pfizer
Completed - verified June 2011
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: gemcitabine; Drug: oxaliplatin; Procedure: radiation therapy
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Sanofi-Aventis; Johns Hopkins University; Princess Margaret Hospital, Canada; Ohio State University
Active, not recruiting - verified February 2012
A Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Completed - verified February 2012
Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer

Condition: Locally Advanced Breast Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Platinum-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified December 2011
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Conditions: Carcinoid Tumor; Acromegaly
Intervention: Drug: Pasireotide
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified March 2012
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

Conditions: Small Cell Lung Carcinoma; Small Cell Lung Cancer
Intervention: Drug: ABT-263
Sponsors: Abbott; Abbott; Genentech
Completed - verified December 2011
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Conditions: Non-Hodgkins Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: Aurora kinase inhibitor AT9283
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Conditions: Advanced Breast Cancer; Advanced Malignant Solid Tumors; Breast Neoplasms
Interventions: Drug: Combination of HKI-272 (neratinib) and paclitaxel; Drug: Combination of HKI-272 and paclitaxel; Drug: Combination of HKI-272 (neratinib) and paclitaxel; Drug: Combination of HKI-272 (neratinib) and paclitaxel
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Active, not recruiting - verified May 2012
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

Condition: Neoplasms
Intervention: Drug: SU011248
Sponsors: Pfizer; Pfizer
Completed - verified December 2011
Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy

Condition: Prostate Cancer
Intervention: Drug: Goserelin Acetate
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); AstraZeneca
Active, not recruiting - verified March 2011
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009
A Randomized Clinical Trial of Megestrol Acetate as an Appetite Stimulant in Malnourished Children With Cancer

Condition: Malnourished Children With Cancer
Interventions: Drug: Megstrol Acetate; Other: Placebo
Sponsors: University of British Columbia; University of British Columbia; University of Alberta
Recruiting - verified October 2011
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Sunitinib + Capecitabine; Drug: Capecitabine
Sponsors: Pfizer; Pfizer
Completed - verified September 2011
A Pilot Study To Evaluate the Effectiveness of Pulsed Time-Domain Optical Spectroscopy for Monitoring the Responses in Neoadjuvant Treatments of Locally-Advanced Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; ART Advanced Research Technologies Inc.
Recruiting - verified April 2012
Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment

Condition: Locally Advanced Breast Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

Conditions: Neoplasms, Uterine Cervix; Metastatic Cervical Cancer
Interventions: Drug: pazopanib (GW786034); Drug: lapatinib (GW572016)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastasizing Breast Cancer (F); Metastatic Castration-Resistant Prostrate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: risedronate; Drug: risedronate; Drug: Control
Sponsors: CMX Research; CMX Research; Sanofi-Aventis
Completed - verified February 2012
Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Drug: gimatecan
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen

Condition: Pancreatic Neoplasms
Interventions: Drug: larotaxel (XRP9881); Drug: 5-Fluorouracil
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified August 2011
An Imaging Pilot Study of 18F-fluoro-3'-Deoxy-3'-L-fluorothymidine (18F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine

Condition: Pancreatic Cancer
Intervention: Procedure: Positron-Emission Tomography (PET) 18F-FLT
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified March 2012
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Biological: Stimuvax; Biological: Placebo
Sponsors: EMD Serono; EMD Serono; Merck KGaA
Active, not recruiting - verified April 2012
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: AC regimen; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified July 2010
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Drug: ZD6474 (Vandetanib)
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified April 2011
Everolimus Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Conditions: Endometrial Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified January 2012
Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: fluorouracil; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified June 2009
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Condition: Bladder Neoplasms
Intervention: Drug: Mycobacterial cell wall-DNA complex
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Active, not recruiting - verified July 2011
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: ZD6474 (vandetanib); Other: Best Supportive Care
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified April 2011
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Sunitinib malate; Drug: Taxotere
Sponsors: Pfizer; Pfizer
Completed - verified July 2011
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Herceptin; Drug: Docetaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

Condition: Lung Cancer, Non-Small Cell
Interventions: Drug: HYCAMTIN, oral capsules; Radiation: Radiation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Sunitinib in Treating Patients With Unresectable, Locally Advanced or Metastatic Cervical Cancer

Condition: Cervical Cancer
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Condition: Malignant Mesothelioma
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified January 2012
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Condition: Thyroid Neoplasms
Intervention: Drug: AG-013736
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma

Conditions: Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: CDKI AT7519; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011
Sunitinib in Treating Patients With Advanced or Metastatic Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified January 2012
Temozolomide and Everolimus in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus; Drug: temozolomide; Genetic: microarray analysis; Other: immunohistochemistry staining method
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: E7389; Drug: Physician's Choice
Sponsors: Eisai Inc.; Eisai Inc.; Eisai Limited
Completed - verified March 2012
Randomized Controlled Trial Comparing MBSR to SET in Breast Cancer Patients

Condition: Breast Neoplasms
Interventions: Behavioral: Mindfulness Meditation-Based Stress Reduction; Behavioral: Supportive-Expressive Group Therapy
Sponsors: Alberta Health Services; Canadian Breast Cancer Research Alliance; British Columbia Cancer Agency
Active, not recruiting - verified August 2011
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

Conditions: Neoplasms, Head and Neck; Cancer
Interventions: Drug: Lapatinib oral tablets; Drug: radiotherapy; Drug: cisplatin chemotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

Condition: Colorectal Cancer
Interventions: Drug: Cediranib; Drug: Bevacizumab; Drug: 5-fluorouracil ( in FOLFOX); Drug: Leucovorin (in FOLFOX); Drug: Oxaliplatin (in FOLFOX)
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified June 2011
E7389 as Second-Line Therapy in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: eribulin mesylate
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Completed - verified July 2009
Zalutumumab in Patients With Non-curable Head and Neck Cancer

Conditions: Head and Neck Cancer; Squamous Cell Cancer
Interventions: Drug: Zalutumumab; Other: Best Supportive Care
Sponsors: Genmab; Genmab
Completed - verified September 2011
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Letrozole; Other: Placebo
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Novartis
Active, not recruiting - verified September 2011
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

Conditions: Bone Neoplasms; Pain, Intractable; Cancer
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsors: Pfizer; Pfizer
Terminated - verified August 2011
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011
A Study of Tarceva After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Tarceva; Drug: Placebo
Sponsors: OSI Pharmaceuticals; OSI Pharmaceuticals; Astellas Pharma Global Development, Inc.
Active, not recruiting - verified March 2012
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Condition: Breast Neoplasms
Interventions: Drug: Capecitabine; Drug: Sunitinib malate
Sponsors: Pfizer; Pfizer
Terminated - verified July 2011
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AEG35156; Drug: docetaxel; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012
Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Condition: Lung Cancer
Intervention: Drug: Motexafin Gadolinium
Sponsors: Pharmacyclics; Pharmacyclics
Completed - verified August 2010
Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients

Condition: Head and Neck Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012
Evaluating Taste and Smell Function and Food and Taste Preferences of Head and Neck Cancer Patients During Radiation Therapy/Chemotherapy

Condition: Head and Neck Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: CP-751,871; Drug: exemestane; Drug: exemestane
Sponsors: Pfizer; Pfizer
Terminated - verified May 2012
A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Condition: Lung Cancer
Interventions: Drug: satraplatin and erlotinib; Drug: erlotinib
Sponsors: Agennix; Agennix
Completed - verified May 2012
A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

Condition: Non-small-cell Lung Cancer
Interventions: Procedure: External radiotherapy; Biological: nimotuzumab
Sponsors: YM BioSciences; YM BioSciences; CIMYM BioSciences
Terminated - verified June 2011
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified August 2009
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Conditions: Lung Cancer; Precancerous Condition; Tobacco Use Disorder
Interventions: Drug: sulindac; Other: placebo
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Completed - verified August 2009
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

Conditions: Neoplasms, Prostate; Prostate Cancer
Interventions: Drug: Dutasteride; Drug: Matching placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

Condition: Colorectal Neoplasms
Intervention: Drug: CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals
Completed - verified May 2012
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Conditions: Islet Cell Carcinoma; Neuroendocrine Carcinoma; Neuroendocrine Tumor; Pancreatic Neoplasms
Intervention: Drug: Everolimus 10 mg
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified March 2012
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: ispinesib; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
AEG35156 and Docetaxel in Treating Patients With Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AEG35156; Drug: docetaxel
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27

Conditions: Breast Cancer; Osteoporosis
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: cholecalciferol; Drug: alendronate sodium; Drug: calcium gluconate; Drug: risedronate sodium; Other: laboratory biomarker analysis; Procedure: dual x-ray absorptometry
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Southwest Oncology Group
Completed - verified January 2012
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified December 2011
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Condition: Bladder Cancer
Interventions: Biological: BCG vaccine; Drug: gefitinib; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurofibromatosis Type 1
Interventions: Drug: carboplatin; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours

Conditions: Lung Neoplasms; Lung Cancer
Intervention: Procedure: Fractionated Stereotactic Radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified January 2012
Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Condition: Lung Cancer
Intervention: Radiation: 3-dimensional conformal radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Paclitaxel and Carboplatin; Drug: NOV-002 Injection in combination with Carboplatin vs. Paclitaxel and Carboplatin
Sponsors: Novelos Therapeutics; Novelos Therapeutics
Completed - verified March 2010
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: pazopanib (GW786034) 400 mg; Drug: lapatinib (GW572016) 1500 mg; Drug: lapatinib (GW572016) 1000 mg; Drug: pazopanib (GW786034) 800 mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: clinical observation; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified February 2012
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Condition: Metastatic Breast Cancer
Interventions: Drug: E7389; Drug: Capecitabine
Sponsors: Eisai Inc.; Eisai Inc.
Completed - verified April 2012
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: Docetaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012
Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

Condition: Retinoblastoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study to Evaluate Safety and Feasibility of Using OGX-011 in Combination With Second Line Chemotherapy in Patients With HRPC

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone; Drug: OGX-011
Sponsors: OncoGenex Technologies; OncoGenex Technologies
Completed - verified July 2011
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Condition: Anemia
Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: Darbepoetin alfa
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified July 2011
Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

Conditions: Neoplasms; Cancer of the Ovary
Interventions: Drug: AVE0005 (VEGF Trap); Drug: AVE0005 (VEGF Trap)
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified August 2011
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Conditions: Ovarian Neoplasms; Ascites
Interventions: Drug: aflibercept (AVE0005 / VEGF Trap); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified July 2011
ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Condition: Ovarian Neoplasms
Intervention: Drug: Sagopilone (ZK 219477) + carboplatin
Sponsors: Bayer; Bayer
Completed - verified November 2011
S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Condition: Gastrointestinal Stromal Tumor
Interventions: Biological: bevacizumab; Drug: imatinib mesylate
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group
Active, not recruiting - verified September 2009
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Conditions: Tumors; Non Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
Sponsors: MethylGene Inc.; MethylGene Inc.
Completed - verified May 2009
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Conditions: Thrombosis; Cancer; Pulmonary Embolism
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ontario Clinical Oncology Group (OCOG)
Completed - verified February 2012
Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours

Conditions: Renal Cell Carcinoma; Neuroendocrine Tumours
Intervention: Drug: 18F-FAZA PET Imaging
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified March 2012
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Conditions: Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: dasatinib
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

Conditions: Advanced Breast Cancer; Metastatic Breast Cancer
Intervention: Drug: Fulvestrant
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified April 2012
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

Condition: Breast Neoplasm
Interventions: Drug: Sagopilone (ZK 219477); Drug: Sagopilone (ZK 219477)
Sponsors: Bayer; Bayer
Completed - verified November 2011
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

Condition: Prostatic Neoplasms
Interventions: Drug: CP-751,871; Drug: docetaxel; Drug: prednisone; Drug: docetaxel; Drug: prednisone
Sponsors: Pfizer; Pfizer
Completed - verified May 2012
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011
Docetaxel in Breast Cancer

Condition: Breast Cancer
Interventions: Drug: docetaxel, doxorubicin, cyclophosphamide; Drug: Docetaxel,doxorubicin, cyclophosphamide
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Cancer International Research Group
Active, not recruiting - verified August 2011
Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: Magnetic Resonance Spectroscopy (3Tesla)
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012
Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: computed tomography; Procedure: positron emission tomography
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2007
PROFIT - Prostate Fractionated Irradiation Trial

Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting - verified October 2011
Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Completed - verified May 2009
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel; Drug: Carboplatin plus Paclitaxel
Sponsors: Bayer; Bayer
Terminated - verified November 2011
COLOR II: Laparoscopic Versus Open Rectal Cancer Removal

Condition: Rectal Cancer
Intervention: Procedure: surgery
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Active, not recruiting - verified March 2010
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Condition: Prophylaxis for HPV Infections and Associated Cervical Neoplasia
Interventions: Biological: Cervarix; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012
Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: Integrated Imaging High Intensity Focused Ultrasound
Sponsors: EDAP TMS S.A.; EDAP TMS S.A.
Active, not recruiting - verified January 2012
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Degarelix; Drug: Leuprolide 7.5 mg
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Completed - verified December 2011
RAPID: Randomized Trial of Accelerated Partial Breast Irradiation

Condition: Breast Cancer
Interventions: Radiation: 3D-CRT APBI; Radiation: WBI
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Canadian Breast Cancer Research Alliance
Active, not recruiting - verified July 2011
Review of Multimodality Management of Anaplastic Thyroid Cancer

Condition: Anaplastic Thyroid Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified July 2011
Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer

Conditions: Lung Cancer, Small Cell; Small Cell Lung Cancer
Intervention: Drug: topotecan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012
Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

Condition: Renal Cell Carcinoma
Intervention: Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Active, not recruiting - verified January 2012
A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

Conditions: Prostatic Neoplasms; Neoplasm Metastasis; Palliative Care
Intervention: Behavioral: Exercise training
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

Conditions: Neoplasms, Endometrial; Endometrial Cancer
Intervention: Drug: topotecan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified September 2009
AZD0530 and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: AZD0530; Drug: gemcitabine hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012
Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases

Conditions: Colorectal Cancer; Liver Metastases
Intervention: Procedure: PET diagnostic imaging
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Active, not recruiting - verified October 2011
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: sunitinib; Drug: erlotinib; Drug: placebo
Sponsors: Pfizer; Pfizer
Completed - verified February 2012
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
Interventions: Drug: EPO906 (Patupilone); Drug: doxorubicin
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Docetaxel and Prednisone With or Without OGX-011 in Treating Patients With Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Condition: Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: docetaxel; Drug: prednisone
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
Iressa v BSC (Best Supportive Care) in First Line NSCLC

Condition: NSCLC
Intervention: Drug: Gefitinib
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified February 2012
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Condition: Breast Cancer
Intervention: Drug: E7389
Sponsors: Eisai Inc.; Eisai Inc.; Eisai Limited
Completed - verified April 2012
Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors

Condition: Breast Cancer
Intervention: Behavioral: Physical exercise
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified April 2012
Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cediranib maleate; Drug: paclitaxel; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified August 2011
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Letrozole, anastrozole
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: SU011248; Drug: Chemotherapy
Sponsors: Pfizer; Pfizer
Completed - verified September 2011
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer

Condition: Breast Neoplasms
Intervention: Drug: SU011248/Trastuzumab
Sponsors: Pfizer; Pfizer
Completed - verified July 2011
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

Condition: Breast Cancer
Interventions: Drug: letrozole; Other: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Condition: Breast Neoplasms
Interventions: Drug: Gefitinib; Drug: Tamoxifen
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified February 2012
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: isotretinoin; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Radiation Therapy or Temozolomide in Treating Patients With Gliomas

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; British Medical Research Council; Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting - verified February 2012
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

Condition: Pancreatic Neoplasms
Interventions: Drug: Gemcitabine; Drug: AG-013736 plus gemcitabine
Sponsors: Pfizer; Pfizer
Completed - verified January 2012
CAFE Study - Cancer Patient Fracture Evaluation

Conditions: Cancer; Spinal Fractures
Interventions: Device: Balloon Kyphoplasty; Other: Non Surgical Management
Sponsors: Medtronic Spine LLC; Medtronic Spine LLC
Completed - verified May 2010
Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.

Condition: Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Completed - verified August 2011
Detection of Early Lung Cancer by Serum Protein Expression Profiling

Condition: Non-small Cell Lung Cancer
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer

Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: strontium-89; Drug: cisplatin
Sponsors: Alberta Health Services; Alberta Health Services; Prostate cancer research foundation; Amersham Health
Completed - verified August 2008
Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

Conditions: Lung Cancer; Mesothelioma
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified January 2012
Early Lung Cancer Detection Using Computed Tomography

Condition: Lung Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified February 2012
Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure

Condition: Head and Neck Cancer
Interventions: Procedure: radiation treatment and surgery; Procedure: radiation alone
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified October 2011
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

Conditions: Multiple Sclerosis; Optic Neuritis; Transverse Myelitis; Acute Brainstem/Cerebellar Syndrome
Intervention: Drug: interferon beta 1a 30 ug IM once weekly
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; Biogen Idec
Completed - verified June 2011
Does Scar Massage Improve Postoperative Pain and Function in Women With Breast Cancer?

Condition: Breast Cancer
Intervention: Procedure: Scar massage.
Sponsors: University of British Columbia; University of British Columbia
Active, not recruiting - verified September 2011
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: luteinizing hormone-releasing hormone (LHRH) short acting or long acting
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012
Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.

Condition: - Breast Cancer
Intervention: Procedure: Aloe barbadensis topical application in a moisturizing cream vehicle.
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified December 2011
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-small Cell Lung Cancer
Intervention: Drug: custirsen sodium
Sponsors: OncoGenex Technologies; OncoGenex Technologies
Completed - verified February 2012
PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers

Condition: Non-small-cell Lung Carcinoma
Intervention: Procedure: PET Imaging
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Active, not recruiting - verified March 2012
Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)

Condition: Non-Small-Cell Lung Carcinoma
Intervention: Procedure: PET Diagnostic Imaging
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Completed - verified November 2011
Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Biological: OGX-011
Sponsors: University of British Columbia; University of British Columbia; Department of Defense
Recruiting - verified April 2012
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011
Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins

Conditions: Lung Cancer; Colorectal Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Terminated - verified April 2012
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer

Condition: Colon Cancer
Intervention: Drug: 5FU/LV
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified December 2011
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Condition: Carcinoma, Renal Cell
Intervention: Drug: Sutent
Sponsors: Pfizer; Pfizer
Approved for marketing - verified March 2012
Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: Hypofractionated radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified October 2011
Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Completed - verified October 2007
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment

Condition: Colon Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: Tomotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified April 2012
Computed Tomotherapy (CT) and Magnetic Resonance Imaging (MRI) Fusion on Radiation Treatment Planning for Patients With Cancer of the Cervix

Condition: Cervix Cancer
Intervention: Procedure: CT and MR fusion
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified December 2011
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation

Condition: Prostatic Neoplasm
Intervention: Procedure: Magnetic Resonance Spectroscopy Imaging
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012
Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services; Calgary Health Region
Completed - verified January 2012
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

Conditions: Skin Neoplasms; Kidney Transplantation
Interventions: Drug: sirolimus; Drug: cyclosporine or tacrolimus
Sponsors: Wyeth is now a wholly owned subsidiary of Pfizer; Wyeth is now a wholly owned subsidiary of Pfizer
Completed - verified April 2012
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Conditions: Human Papillomavirus (HPV) Infection; Cervical Neoplasia
Interventions: Biological: Cervarix™; Biological: Havrix™-based investigational formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation

Conditions: Prostate Cancer; Osteoporosis
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified December 2011
Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer

Condition: Cervix Cancer
Intervention: Procedure: Megavoltage CT scan
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified April 2012
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer

Conditions: Brain Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Colorectal Neoplasms; Lymphoma
Intervention: Procedure: Positron Emission Tomography (PET) scan
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence

Conditions: Sarcoma; Multiple Myeloma; Testicular Neoplasms; Ovarian Neoplasms; Kidney Neoplasms
Intervention: Procedure: Positron Emission Tomography
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer

Condition: Lung Neoplasms
Intervention: Procedure: Positron Emission Tomography (PET) scan Imaging
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012
A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers

Conditions: Breast Cancer; Glioma; Prostate Cancer; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell-Lung; Head and Neck Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified March 2012
A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer

Conditions: Rectal Cancer; Neoplasm Metastasis
Interventions: Drug: Capecitabine; Procedure: Pelvic radiation
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified August 2011
Biological Imaging for Optimising Clinical Target Volume (CTV) and Gross Tumour Volume (GTV) Contouring in Prostate Cancer to Improve the Possibilities for Intensity Modulated RadioTherapy (IMRT) Dose Escalation

Condition: Prostate Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Terminated - verified December 2011
Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Terminated - verified April 2012
CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy

Condition: Cervix Cancer
Interventions: Radiation: Radiotherapy; Radiation: Radiotherapy; Radiation: Radiotherapy/Cisplatin; Radiation: Radiotherapy/Cisplatin
Sponsors: International Atomic Energy Agency; International Atomic Energy Agency
Completed - verified October 2011
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Completed - verified December 2011
A Safety and Efficacy Study in Patients With Gastric Cancer

Condition: Gastric Cancer
Interventions: Drug: S-1/Cisplatin; Drug: 5-FU/cisplatin
Sponsors: Taiho Pharma USA, Inc.; Taiho Pharma USA, Inc.; Quintiles
Completed - verified March 2012
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: Trabectedin; Drug: DOXIL; Drug: DOXIL
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar
Completed - verified April 2012
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers

Conditions: Chronic Myelogenous Leukemia; Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); Hypereosinophilic Syndrome; Systemic Mastocytosis
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012
Combination Chemotherapy and Cyclosporine Followed By Cryotherapy and/or Laser Therapy in Treating Patients With Newly Diagnosed Retinoblastoma in Both Eyes

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cyclosporine; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser therapy; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); The Hospital for Sick Children
Recruiting - verified April 2009
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors

Conditions: Brain and Central Nervous System Tumors; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: valproic acid
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

Condition: Breast Neoplasm
Interventions: Drug: RAD001, Letrozole 2.5mg; Drug: Letrozole 2.5mg
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified November 2011
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)

Conditions: Preneoplastic Conditions; Prostatic Intraepithelial Neoplasia
Interventions: Drug: Toremifene 20 mg; Drug: Placebo
Sponsors: GTx; GTx
Completed - verified October 2010
Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: conventional surgery; Procedure: therapeutic thoracoscopy; Radiation: brachytherapy; Radiation: iodine I 125
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Active, not recruiting - verified January 2010
Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Conditions: Adenocarcinoma; Neoplasms
Intervention: Drug: Torisel
Sponsors: Pfizer; Pfizer
Completed - verified February 2012
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Bayer
Completed - verified January 2012
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (VELCADE); Drug: Bortezomib (VELCADE); Drug: Doxorubicin hydrochloride (DOXIL/CAELYX)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Active, not recruiting - verified May 2012
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Colorectal Cancer; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lymphoma; Melanoma (Skin); Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: lapatinib ditosylate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified April 2012
Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Conditions: Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Drug: amifostine trihydrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

Condition: Liver Cancer
Intervention: Drug: ispinesib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

Conditions: Lung Cancer; Metastatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: temozolomide; Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified August 2009
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: cetuximab; Drug: Pemetrexed
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Completed - verified September 2011
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: ispinesib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Conditions: Melanoma; Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody; Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified June 2011
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Condition: Gastrointestinal Neoplasm
Intervention: Drug: Sutent
Sponsors: Pfizer; Pfizer
Approved for marketing - verified March 2012
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: sorafenib tosylate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Placebo; Drug: ZD4054 (Zibotentan)
Sponsors: AstraZeneca; AstraZeneca
Completed - verified September 2011
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer

Condition: Breast Cancer
Interventions: Other: immunohistochemistry staining method; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified April 2011
RNA-Loaded Dendritic Cell Cancer Vaccine

Condition: Renal Cell Carcinoma
Intervention: Biological: MB-002
Sponsors: Argos Therapeutics; Argos Therapeutics
Completed - verified January 2012
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified January 2012
GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: GTI-2040; Drug: docetaxel; Drug: prednisone
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Completed - verified November 2005
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: cetuximab; Drug: carboplatin
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified September 2005
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

Conditions: Breast Neoplasms; Neoplasm Metastasis
Interventions: Drug: Temsirolimus (CCI-779) for 34 months; Drug: Letrozole for 34 months
Sponsors: Wyeth is now a wholly owned subsidiary of Pfizer; Wyeth is now a wholly owned subsidiary of Pfizer
Terminated - verified November 2011
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012
Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears

Conditions: Cervical Cancer; Precancerous Condition
Interventions: Procedure: Colposcopic biopsy; Procedure: Light-Scattering Spectroscopy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed - verified July 2011
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Grupo Espanol de Investigacion del Cancer de Mama; UNICANCER
Active, not recruiting - verified August 2011
Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases

Conditions: Metastatic Cancer; Pain
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Trans-Tasman Radiation Oncology Group (TROG); Cancer Research UK; Dutch Bone Metastasis Study Group; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011
Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Conditions: Kidney Cancer; Leukemia; Lymphoma; Neuroblastoma; Oral Complications; Sarcoma
Intervention: Dietary Supplement: Traumeel S
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Completed - verified November 2009
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme

Condition: Glioblastoma Multiforme
Interventions: Drug: IL13-PE38QQR; Procedure: surgery and catheter placement (2 procedures); Drug: prolifespan 20 with carmustine implant (GLIADEL® Wafer); Procedure: surgery and wafer placement (1 procedure)
Sponsors: Insys Therapeutics Inc; Insys Therapeutics Inc
Completed - verified June 2011
Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions

Condition: Lung Cancer
Interventions: Genetic: proteomic profiling; Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Completed - verified April 2006
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Placebo; Drug: Docetaxel; Drug: AG-013736 (axitinib); Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Completed - verified February 2012
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: fulvestrant
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group
Active, not recruiting - verified June 2011
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer

Condition: Pancreatic Cancer
Interventions: Biological: cetuximab; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group
Completed - verified April 2012
Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers

Conditions: Leukemia; Myeloproliferative Disorders; Myelodysplastic-Myeloproliferative Diseases
Interventions: Biological: Allogeneic bone marrow transplantation; Biological: Peripheral blood stem cell transplantation
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Active, not recruiting - verified January 2012
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib (GW572016); Drug: Letrozole
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Condition: Carcinoma, Renal Cell
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Bayer; Onyx Pharmaceuticals
Completed - verified November 2011
CCI-779 in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Drug: temsirolimus
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); NCIC Clinical Trials Group; Eastern Cooperative Oncology Group
Active, not recruiting - verified April 2011
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

Conditions: Extragonadal Germ Cell Tumor; Testicular Germ Cell Tumor
Interventions: Drug: cisplatin; Drug: ifosfamide; Drug: paclitaxel; Drug: vinblastine
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Terminated - verified June 2011
Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: breast imaging study; Procedure: comparison of screening methods; Procedure: magnetic resonance imaging; Procedure: radiomammography; Procedure: ultrasound imaging
Sponsors: National Cancer Institute (NCI); American College of Radiology Imaging Network; National Cancer Institute (NCI)
Completed - verified February 2006
Ecteinascidin 743 in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

Condition: Sarcoma
Interventions: Drug: trabectedin; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified January 2012
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Procedure: allogeneic bone marrow transplantation
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

Condition: Colorectal Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: Leucovorin; Drug: 5 FU; Drug: Oxaliplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified July 2011
A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: Oxaliplatin; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5 FU; Drug: Avastin; Drug: Avastin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified July 2011
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: Oxaliplatin; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5 FU
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified September 2011
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group; International Breast Cancer Study Group
Completed - verified September 2011
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Active, not recruiting - verified February 2012
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: docetaxel; Drug: epirubicin hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Active, not recruiting - verified May 2010
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma

Conditions: Carcinoma, Renal Cell; Kidney Neoplasms
Interventions: Drug: Interferon Alfa; Drug: CCI-779; Drug: Interferon Alfa and CCI-779
Sponsors: Pfizer; Pfizer
Completed - verified June 2011
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Conditions: Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Exemestane
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

Conditions: Non-Small-Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Drug: Topotecan/Docetaxel combination; Drug: Docetaxel
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Condition: Multiple Myeloma
Intervention: Drug: bortezomib
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Completed - verified January 2012
GW572016 For Treatment Of Refractory Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer; Neoplasms, Breast
Intervention: Drug: GW572016
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified October 2008
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Drug: carboplatin; Drug: cytarabine; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
S0227 Comparison of Cisplatin Combined With Either Paclitaxel or Gemcitabine in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified June 2011
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

Conditions: Neoplasms, Prostate; Prostate Cancer
Interventions: Drug: Dutasteride; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: tamoxifen citrate; Radiation: Radiation Therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); North Central Cancer Treatment Group; Southwest Oncology Group; American College of Surgeons
Active, not recruiting - verified January 2012
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Completed - verified July 2011
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer

Conditions: Esophageal Cancer; Gastric Cancer
Interventions: Drug: cisplatin; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: leucovorin calcium; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); North Central Cancer Treatment Group; Eastern Cooperative Oncology Group
Active, not recruiting - verified April 2011
Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

Condition: Neuroblastoma
Intervention: Drug: fenretinide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Gefitinib in Treating Patients With Non-Small Cell Lung Cancer That Has Been Surgically Removed

Condition: Lung Cancer
Interventions: Drug: IRESSA (ZD1839); Other: Placebo comparator
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Completed - verified January 2012
Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone; Drug: thalidomide; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Active, not recruiting - verified September 2011
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: bortezomib
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Completed - verified January 2012
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor
Interventions: Biological: filgrastim; Biological: graft-versus-tumor induction therapy; Drug: carboplatin; Drug: etoposide; Drug: ifosfamide; Drug: thiotepa; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Trastuzumab in Treating Women With Primary Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Procedure: adjuvant therapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; International Breast Cancer Study Group
Active, not recruiting - verified March 2012
S0124: Cisplatin Combined With Either Irinotecan or Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: etoposide; Drug: irinotecan hydrochloride
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Active, not recruiting - verified June 2011
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Condition: Lymphoma
Intervention: Drug: bortezomib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Completed - verified September 2011
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: monoclonal antibody 11D10 anti-idiotype vaccine; Biological: monoclonal antibody GD2 anti-idiotype vaccine; Drug: cisplatin; Drug: etoposide; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified June 2011
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Condition: Pancreatic Cancer
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774)
Sponsors: OSI Pharmaceuticals; OSI Pharmaceuticals; NCIC Clinical Trials Group
Completed - verified November 2011
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-small-cell Lung
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774 )
Sponsors: OSI Pharmaceuticals; OSI Pharmaceuticals; NCIC Clinical Trials Group
Completed - verified November 2011
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms
Intervention: Drug: epothilone b
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Conditions: Gastrointestinal Stromal Tumor; Metastatic Cancer; Neuroblastoma; Sarcoma
Intervention: Drug: imatinib mesylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified September 2004
Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified August 2011
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: Paclitaxel
Sponsors: Eastern Cooperative Oncology Group; Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Completed - verified January 2010
Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: filgrastim; Biological: sargramostim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: tirapazamine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: exatecan mesylate; Drug: gemcitabine hydrochloride
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Completed - verified May 2012
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Standard Treatment; Drug: capecitabine
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group; NCIC Clinical Trials Group
Active, not recruiting - verified June 2011
Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer

Condition: Prostate Cancer
Interventions: Procedure: conventional surgery; Radiation: brachytherapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Completed - verified October 2003
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Condition: Sarcoma
Interventions: Biological: filgrastim; Biological: trastuzumab; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Drug: releasing hormone agonist therapy; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group
Completed - verified January 2005
S0023: Combination Chemo Plus RT With or Without Gefitinib in Treating Patients With Unresectable Stage III NSCLC

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: etoposide; Drug: gefitinib; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; NCIC Clinical Trials Group
Completed - verified June 2011
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified March 2008
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

Conditions: Anemia; Cervical Cancer; Drug/Agent Toxicity by Tissue/Organ; Radiation Toxicity
Interventions: Biological: epoetin alfa; Drug: cisplatin; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group
Completed - verified May 2004
DX-8951f in Treating Patients With Metastatic Stomach Cancer

Conditions: Esophageal Cancer; Gastric Cancer
Intervention: Drug: exatecan mesylate
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Completed - verified May 2012
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: epoetin alfa; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - verified May 2012
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

Condition: Colorectal Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: Leucovorin; Drug: 5-FU
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified November 2011
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone; Drug: thalidomide
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: aldesleukin; Biological: filgrastim; Drug: asparaginase; Drug: busulfan; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: fludarabine phosphate; Drug: idarubicin; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: thioguanine; Procedure: allogeneic bone marrow transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified October 2002
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride
Sponsors: National Cancer Institute (NCI); AGO Study Group; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Active, not recruiting - verified June 2011
External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: brachytherapy; Radiation: iodine I 125; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified February 2012
Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: tamoxifen citrate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified May 2006
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011
Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: rebimastat
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified August 2011
Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); Radiation Therapy Oncology Group; Southwest Oncology Group; Trans-Tasman Radiation Oncology Group (TROG); North Central Cancer Treatment Group
Active, not recruiting - verified October 2011
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: aromatase inhibition therapy; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Drug: tamoxifen citrate; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Active, not recruiting - verified January 2006
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Condition: Sarcoma
Intervention: Drug: alvocidib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Treating Women With Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting - verified June 2011
Topotecan in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: vinblastine; Procedure: adjuvant therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group; USC/Norris Comprehensive Cancer Center
Active, not recruiting - verified June 2011
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group
Completed - verified February 2004
Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer

Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified May 2012
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: isotretinoin; Drug: melphalan; Drug: topotecan hydrochloride; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: bone marrow ablation with stem cell support; Procedure: conventional surgery; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: AC-T regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: endocrine-modulating drug therapy; Drug: paclitaxel; Drug: tamoxifen citrate; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified January 2012
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified March 2012
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer

Condition: Colorectal Cancer
Interventions: Drug: FOLFIRI regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); North Central Cancer Treatment Group; NCIC Clinical Trials Group; Southwest Oncology Group; Eastern Cooperative Oncology Group
Completed - verified December 2011
Vinorelbine Plus Cisplatin or No Further Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Surgically Removed

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: vinorelbine ditartrate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; Cancer and Leukemia Group B
Completed - verified March 2012
Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified April 2003
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Drug: ISIS 5132
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer

Condition: Colorectal Cancer
Interventions: Procedure: conventional surgery; Procedure: laparoscopic surgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting - verified October 2002
Hormone Therapy in Treating Men With Stage IV Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified April 2009
Letrozole After Tamoxifen in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; International Breast Cancer Study Group; Eastern Cooperative Oncology Group; Southwest Oncology Group; Cancer and Leukemia Group B; European Organization for Research and Treatment of Cancer - EORTC
Completed - verified March 2012
Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: marimastat; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: cyproterone acetate; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: nilutamide
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Southwest Oncology Group
Active, not recruiting - verified April 2012
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: octreotide acetate; Drug: tamoxifen citrate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

Condition: Breast Cancer
Interventions: Drug: Raloxifene; Drug: Tamoxifen
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Eli Lilly and Company; AstraZeneca
Active, not recruiting - verified September 2011
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group; Southwest Oncology Group
Completed - verified December 2011
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified September 2011
Monoclonal Antibody Therapy Compared With No Further Therapy After Surgery in Treating Patients With Stage II Colon Cancer

Condition: Colorectal Cancer
Intervention: Biological: edrecolomab
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Completed - verified August 2011
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2011
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified February 2012
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: nilutamide; Procedure: orchiectomy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group; Medical Research Council
Completed - verified January 2012
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Procedure: surgical resection
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Completed - verified April 2011
Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery

Condition: Endometrial Cancer
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified April 2012
Talc in Treating Patients With Malignant Pleural Effusion

Condition: Metastatic Cancer
Interventions: Drug: talc; Drug: Talc
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; North Central Cancer Treatment Group
Completed - verified March 2011
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: thioguanine
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Combination Chemotherapy in Treating Patients With Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: melphalan; Drug: prednisone
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011
Surgery in Treating Children With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: filgrastim; Biological: sargramostim; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Procedure: adjuvant therapy; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified August 2011
Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Drug: danazol
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified July 2004
Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

Condition: Lung Cancer
Interventions: Other: immunohistochemistry staining method; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Completed - verified October 2004
Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Active, not recruiting - verified July 2003
Tretinoin, Cytarabine, and Daunorubicin With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology Group; Children's Oncology Group
Active, not recruiting - verified June 2011
Combination Chemotherapy in Treating Children With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: filgrastim; Biological: sargramostim; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Suspended - verified July 2011
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

Conditions: Cardiac Toxicity; Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified March 2012
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Biological: filgrastim; Biological: sargramostim; Drug: cyclophosphamide; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Conditions: Anemia; Breast Cancer; Chronic Myeloproliferative Disorders; Drug/Agent Toxicity by Tissue/Organ; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: epoetin alfa; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified November 2006
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: cisplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified January 2012
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified December 2011
Chemotherapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Surgically Removed

Condition: Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: levamisole hydrochloride
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group
Completed - verified December 2011
SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed

Condition: Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: levamisole hydrochloride; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; North Central Cancer Treatment Group; NCIC Clinical Trials Group; Cancer and Leukemia Group B
Active, not recruiting - verified March 2012
Combination Chemotherapy in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); North Central Cancer Treatment Group; Eastern Cooperative Oncology Group; Southwest Oncology Group
Active, not recruiting - verified March 2011
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: axillary lymph node dissection; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Active, not recruiting - verified September 2004
Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus

Conditions: Endometrial Cancer; Sarcoma
Interventions: Procedure: conventional surgery; Procedure: laparoscopic surgery
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified September 2005
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas

Condition: Pancreatic Cancer
Interventions: Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Completed - verified April 2003
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus

Condition: Esophageal Cancer
Interventions: Drug: chemotherapy; Drug: cisplatin; Drug: fluorouracil; Radiation: low-LET electron therapy; Radiation: low-LET photon therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; North Central Cancer Treatment Group
Completed - verified June 2011
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: temozolomide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: New York University School of Medicine; New York University School of Medicine
Withdrawn - verified June 2011
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia

Condition: Gestational Trophoblastic Tumor
Interventions: Biological: dactinomycin; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Completed - verified August 2007